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Abstract

Metabolic syndrome is a clustering of risk factors that make a person more susceptible to
cardiovascular disease and diabetes, and subsequently kidney disease. The overall metabolic
health of American society is decreasing at an alarming rate. Metabolic syndrome is difficult to
study due to its multi-factorial nature, which can vary from study to study. This work utilizes a
meta-analysis to examine the trends in changes of gene expression that occur in rat kidneys from
three different models of metabolic syndrome. Microarray studies used for this analysis were
GSE4800, and GSE7193 obtained from the Gene Expression Omnibus, and E-MEXP-1695
obtained from the European Bioinformatics Institute. Following processing, 88 genes were
found to be significant, including 73 upregulated genes, and 15 downregulated genes.
Approximately 42.0% of the significant genes had already been associated with metabolic
syndrome. Five novel genes were chosen to examine in further detail using real time PCR.
These genes include downregulated genes RGD1309350, and Klk1c9 and upregulated genes
Stk32c, Ampd3, and Mgmt. Preliminary qPCR results verified the trends found through metaanalysis for Klk1c9, and Mgmt, but not for the remaining three genes. Future work involves
continuing to verify the gene expression with qPCR.
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Background

In recent years, the overall metabolic health of the general population has been steadily
decreasing contributing to an exponential increase in disease and health care costs. This
decrease in metabolic health has been attributed to poor diets high in fat and sugar along with an
increase in sedentary lifestyles (Hong et al., 2014). It is thought that there is a genetic
component to obesity and subsequent metabolic dysfunction as well. As a result of this shift in
diet and activity level, many more people are becoming obese, and developing health
complications. Due to this increased prevalence of metabolic disease the term metabolic
syndrome (MetS) was generated to describe a clustering of risk factors for health complications
such as kidney disease, cardiovascular disease (CVD), and stroke. It is estimated that 20-25% of
the world’s adult population have metabolic syndrome (Alberti, Zimmet, Shaw, & Grundy,
2006). Insulin resistance is also thought to underlie MetS, and in conjunction with other risk
factors, can significantly increase a patient’s risk for type 2 diabetes mellitus (T2DM) (Grundy et
al., 2004). Patients with metabolic syndrome have a 5-fold greater risk in developing T2DM,
and up to 80% of patients with T2DM will develop CVD (Grundy, 2007). Patients with
metabolic syndrome are at a high risk for renal complications such as microalbuminuria and/or
chronic kidney disease (Locatelli, Pozzoni, & Del Vecchio, 2006). Kidney damage (as signaled
by microalbuminuria) is also an integral factor in cardiovascular disease risk assessment because
many patients with microalbuminuria (especially diabetic patients) have increased
atherosclerosis (Gobal, Deshmukh, Shah, & Mehta, 2011). Patients with metabolic syndrome
have a 2-fold higher chance of developing CVD (Grundy, 2007). It is recommended that weight
reduction and an increase in physical activity be used to combat the growing prevalence of such
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disease (Grundy, 2012). These factors contribute to the necessity of expanding this area of
research.
Metabolic Syndrome
The term metabolic syndrome is a relatively new description for a group of risk factors that,
when present together, can increase a person’s risk for coronary artery disease, stroke, type 2
diabetes, and kidney disease. Although this condition is rapidly increasing in prevalence, it is
not yet clearly defined in the literature. There are a variety of definitions of metabolic syndrome,
coming from different organizations, which are summarized in the following discussion and in
Table 1.
The National Cholesterol Education Program’s Adult Treatment Panel III (ATP III)
classifies metabolic syndrome using the following criteria: waist circumference > 102 cm (>40
in) for men and > 88 cm (>35 in) for women, triglycerides (TG) ≥ 150 mg/dL, HDL cholesterol
< 40 mg/dL for men and < 50 mg/dL for women, blood pressure ≥ 130/85 mmHg and fasting
blood glucose level ≥ 110 mg/dL. Metabolic syndrome can be diagnosed when 3 of the
previously listed risk factors are present. Although many patients meeting this criterion for MetS
do have insulin resistance, it is not required in order to be diagnosed with MetS (Grundy et al.,
2004).
According to the World Heath Organization, insulin resistance (as indicated by T2DM,
impaired fasting glucose, or impaired glucose tolerance) is required in addition to two other
MetS risk factors. The risk factors include: high blood pressure (≥140/90 mmHg), plasma
triglycerides ≥ 150 mg/dL (≥1.7 mmol/L), HDL cholesterol < 35 mg/dL (0.9 mmol/L) in men or
< 39 mg/dL (1.0 mmol/L) in women, BMI > 30 kg/m2 and/or waist:hip ratio > 0.9 in men and >
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0.85 in women, and urinary albumin excretion rate ≥ 20 µg/min or albumin:creatine ratio ≥ 30
mg/g (Grundy et al., 2004).
The European Group for the Study of Insulin Resistance (EGIR) requires insulin
resistance in conjunction with two or more of the following: central obesity (waist circumference
≥ 94 cm for males and ≥ 80 cm for females), dyslipidemia (triglycerides ≥ 2.0 mmol/L),
hypertension (blood pressure ≥ 140/90 mm Hg, and a fasting plasma glucose ≥ 6.1 mmol/L
(Bloomgarden, 2004).
The International Diabetes Federation (IDF) defines metabolic syndrome as having
central obesity (waist circumference defined by ethnicity-specific values) and two of the
following: raised triglycerides (>150 mg/dL), reduced HDL cholesterol (<40 mg/dL for males,
<50 mg/dL for females), raised blood pressure (systolic >130 mm Hg, diastolic >85 mm Hg),
and raised fasting plasma glucose (>100 mg/dL or previously diagnosed T2DM) (Alberti et al.,
2006).
This inconsistency in definitions further exemplifies the necessity of more research in this
area of metabolism, and shows why its clinical determination is often complicated. However,
most epidemiological studies have used the ATP III definition based on its easy utility in the
clinical setting (Singh & Kari, 2013). Given the presence of such a wide array of components
and criteria, a decision had to be made as to what criteria and definition would be used in this
thesis to diagnose MetS. The definition of MetS used in this study was made stringently so that
it would be an inclusive mixture similar to most of the definitions: where two or more risk
factors are occurring in conjunction with insulin resistance (in our case, each study has 3 risk
factors in conjunction with insulin resistance).
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Table 1. Criteria for diagnosing MetS based on differing criteria of various organizations.

Organization

Components of MetS

The National
Cholesterol
Education
Program’s Adult
Treatment Panel
III
World Health
Organization

Waist circumference ≥ 102 cm or 40 in (male), ≥ 88 cm or 35 in
(female)
TG ≥ 1.7 mmol/L (150 mg/dl)
HDL-C < 40 mg/dL (male), < 50 mg/dL (female)
Blood Pressure ≥ 130/85 mmHg
Fasting plasma glucose ≥ 6.1 mmol/L (110 mg/dL)
Waist:hip ratio > 0.90 (male), > 0.85 (female) or BMI > 30 kg/m2
TG ≥ 2.0 mmol/L and HDL-C ≤ 0.9 mmol/L (male), ≤ 1.0 mmol/L
(female)
Blood Pressure ≥ 140/90 mmHg
Microalbuminuria: Urinary albumin excretion ratio ≥ 20 µg/min or
albumin:creatine ratio ≥ 30 mg/g

European Group
for the Study of
Insulin
Resistance

Waist circumference ≥ 94 cm or 37 in (male), ≥ 80 cm or 31.5 in
(female)
TG ≥ 2.0 mmol/L and/or HDL-C < 1.0 mmol/L
Blood Pressure ≥ 140/90 mmHg
Fasting plasma glucose ≥ 6.1 mmol/L

International
Diabetes
Federation

TG ≥ 150 mg/dL (1.7 mmom/L)
HDL < 40 mg/dL (1.03 mmol/L) in males, < 50 mg/dL (1.29 mmol/L)
in females
Blood Pressure > 130/85
Fasting Plasma Glucose > 100 mg/dL (5.6 mmol/L)

Requirements for
Diagnosis
Must have 3 or
more components

Insulin resistance
indicated by the
presence of
diabetes mellitus,
impaired fasting
glucose, or
impaired glucose
tolerance and 2 or
more components
Insulin resistance
as the top 25% of
the fasting insulin
values among nondiabetic individuals
and 2 or more
components
Central obesity and
2 or more
components

Insulin Resistance
Although each organization has a slightly different definition of MetS, insulin resistance is a
recurring factor in a majority of the definitions. This suggests that insulin resistance underlies
the pathology metabolic syndrome by some mechanism, and thus it is important to define insulin
resistance and explain its role in the pathology of MetS.
Insulin resistance is another term for reduced insulin sensitivity in tissues that are capable
of responding to insulin. When the tissues are insulin resistant, increased glucose transport does
not occur after insulin stimulation, and thus glucose remains in the blood. This often leads to a
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state of hyperinsulinemia where more and more insulin is secreted in response to hyperglycemia.
Often, the overproduction of insulin tires out the pancreatic beta cells (cells that produce insulin),
and when they are no longer able to produce insulin, the patients becomes hyperglycemic
(pertaining to high blood glucose) (Alberti et al., 2006).
The presence of insulin resistance is often signaled by hyperglycemia and glucose
intolerance, which are two diagnostic indices for T2DM. Upon assessment of acute and chronic
T2DM, it itself classifies as a risk factor for CVD. In addition, insulin resistance independently
has been linked to a risk of CVD, as well as a rise in blood pressure. Insulin resistance has also
been linked to obesity, where a rise in fat content correlates with increasing insulin resistance
(Grundy et al., 2004). Insulin resistance mediates many of the risk factors for MetS, which
shows the prevalent role insulin resistance is playing in its diagnosis.
Patients with metabolic syndrome have a 5-fold increase in diabetes risk compared to
healthy individuals, which contributes to an association of metabolic syndrome with a prediabetic state (Stern, Williams, Gonzalez-Villalpando, Hunt, & Haffner, 2004). Since metabolic
syndrome is becoming an increasingly prevalent precursor to heart disease, diabetes, and kidney
disease, the goal of this project is to examine genes that are likely to be influential in the
pathology of metabolic syndrome in the kidney. This could give valuable insight into possible
causes of metabolic syndrome, which could aid in studying the various conditions that often stem
from metabolic dysfunction.
Functions of the Kidney
The main function of the kidneys is to recondition the blood to remove toxins, and retain
nutrients producing urine as the waste product. Urine is composed of metabolic wastes that the
body needs to move along with water. Water is removed in specific quantities to regulate the

11

osmolarity of bodily fluids. Blood flows through a series of glomeruli, which are tangles of
blood vessels surrounded by a cup-shaped structure called the Bowman’s capsule. The kidneys
are efficient at filtering the blood, due to the high pressure on the glomerular capillaries. The
wastes that are filtered from the blood form urine. Before the urine is fully formed, many solutes
and water are reabsorbed into the blood. The urine is collected in the renal tubule and later joins
the collecting ducts to travel to the bladder for excretion (Frayn, 2010). Figure 1 shows the
general anatomy of the kidney, and the functional unit of the kidney, the nephron.

Figure 1. General Kidney Anatomy. Retrieved from http://www.unckidneycenter.org/images/glomerulus.jpg on
4/07/14.

Renal Complications of Metabolic Syndrome
Patients with metabolic syndrome are at a high risk for renal complications such as
microalbuminuria and/or chronic kidney disease (Locatelli et al., 2006). Metabolic syndrome
patients have a 2.5-fold higher risk of CKD and a 2-fold higher risk of microalbuminuria as
compared to a healthy individual (Singh & Kari, 2013). Microalbuminuria occurs when small
amounts of protein (albumin) are lost via the urine due to pathology in glomerular filtration,
when it would normally be returned to the bloodstream when the kidneys are functioning
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correctly. The kidneys are at risk for damage from chronic kidney disease (CKD) in patients
with metabolic syndrome as a result of atherosclerotic vascular damage (Okada et al., 2013).
The pathologic effects of metabolic syndrome on the kidney can be manifested in the following
ways: tubular atrophy, interstitial fibrosis, and global and segmental sclerosis. It is hypothesized
that the combination of insulin resistance, hypertension, dyslipidemia and inflammation result in
increased expression of adipocytokines, angiotensin, inflammatory cytokines such as interleukin
(IL)-6 and tumor necrosis factor α (TNFα), which results in renal fibrosis (Singh & Kari, 2013).
The high blood glucose (hyperglycemia) noted in many cases of metabolic syndrome may also
be contributing to glomerular damage. Microalbuminuria has also been noted in individuals in
this pre-diabetic state, which is of concern because it may indicate CKD. A pre-diabetic state is
one is which blood glucose levels are elevated, but not enough to be diagnosed as diabetes
(Grundy, 2012). Since a pre-diabetic state can lead to T2DM, the kidney is a valuable organ to
study in relation to metabolic syndrome because diabetes can lead to diabetic nephropathy,
which is a common microvascular complication of T2DM (Frayn, 2010). These conditions can
result in renal failure, making it necessary for the patient to receive dialysis to filter toxins and
metabolic wastes out of the blood.

Goals of this Thesis
Based on the widespread pathologic effects of metabolic syndrome, this thesis aims to:
1. Further understand the pathologic effects of metabolic syndrome on the kidney by examining
changes in gene expression caused by metabolic syndrome in the kidney throughout the rat
genome to determine which genes should be examined in further detail.
2. Verify selected results using real-time polymerase chain reaction.
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Microarray Analysis
Microarray analysis is used in this project to study changes in gene expression caused by
metabolic syndrome that may lead to kidney disease. Microarrays are a research tool aimed at
indentifying patterns of gene expression among an entire genome. Each microarray slide is
printed with the entire genome of the organism of interest, using small fragments of
complementary DNA (cDNA) for each gene. The cDNA is arranged in a grid-like pattern
allowing for each gene to have a precise location on the microarray slide (Figure 2). There are
two distinct types of microarray analysis: single-channel arrays and two-channel arrays.
Microarray data from 3 different studies will be combined and analyzed in this thesis, from
single channel arrays.

Figure 2. Example of a microarray slide, where each bead represents a distinct gene in the rat genome. This figure
shows more nucleotides per individual gene than the arrays used in this thesis. Image source: Dr. Terrie Rife,
James Madison University.
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Messenger RNA (mRNA) is isolated and extracted from kidney tissues of both the wildtype and experimental groups. The mRNA is reverse transcribed into cDNA and is hybridized to
the microarray slide. The wild-type and experimental samples are each hybridized to different
microarray slides in addition to rat genomic cDNA. In a single channel array, the wild-type and
experimental cDNA samples are tagged with a red florescent dye, while rat genomic cDNA is
labeled with a green fluorescent dye. The slides are then scanned to determine the ratio of red to
green pixels for each gene. The green genomic cDNA is a universal standard, so the ratios are
treated as absolute levels of gene expression and are compared between the wild-type and
experimental group to determine if a gene is upregulated or downregulated.
Meta-Analysis
A meta-analysis is a technique used to combine data sets from multiple different sources. Since
metabolic syndrome includes many factors contributing to its clinical diagnosis, a meta-analysis
can be used to combine these factors and thus gain a wider understanding of the possible genes
involved in metabolic syndrome. There are now a large variety of studies related to metabolic
syndrome or the components of it; many of which employ microarray technology to investigate
genes related to distinct components of metabolic syndrome.
However, based on the costly nature of using microarrays, these studies are often narrow
in scope (investigate only one condition or aspect of a condition) and have small data sets. Using
a meta-analysis, the data for specific conditions as a whole can be combined and be directly
compared although there are likely to be differences in experimental protocols. This is an
inexpensive way to investigate multivariate conditions such as MetS using data from studies
more concentrated to a single factor of the condition. Using a meta-analysis increases the sample
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size and subsequently the statistical power of the results (Choi, Yu, Kim, & Yoo, 2003). Figure
3 demonstrates the technique of using a meta-analysis as applied to this thesis.
Three different studies, each investigating a specific aspect of MetS, were used to analyze
the common genes between the three studies, and determine changes in gene expression caused
by risk factors for MetS. The meta-analysis is used to determine which changes in gene
expressions overlap between the studies. Since all three risk factors can be present together and
denote a MetS condition, genes that overlap in all three studies may be influential in the
regulation and pathology of MetS. For example, in Figure 3 below, while Gene B and Gene C
may be significant in two of the three studies, only Gene A is significant in all three studies. The
conclusion drawn from this hypothetical data would be that Gene A could be playing a role in
MetS, and thus should be further investigated.

Figure 3. Venn Diagram showing the meta-analysis technique. Each study has insulin resistance and the
characteristics identified above. The intersections show which genes were significant in the overlapping studies.
Gene A was significant in all three studies and thus should be examined further.
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Purpose

Due to the increasing prevalence of MetS and its complications, metabolic disease has gained
increased awareness and attention for the general public and scientists. Because of its
multivariate nature and multi-factorial effects, scientific literature has had significant difficulty in
determining the exact mechanism underlying MetS and its pathogenesis. Three studies, which
are detailed in the Methods section of this thesis, were chosen to represent MetS. For all of the
studies, single channel microarray data for the kidney was available, and a revised statistical
protocol from a previous study was used to isolate upregulated and downregulated genes. This
thesis aims to determine what genes are upregulated and which genes are downregulated in
kidneys of rodent models with metabolic syndrome. Once identified, further real-time PCR
analysis will be completed to verify the accuracy of the meta-analysis data. The answers to these
questions will be used to infer as to which genes could be playing a central role in the pathology
of MetS.
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Methods

Data Collection
In order to collect microarray data related to MetS, existing studies concerning various
characteristics of MetS were obtained via the National Center for Biotechnology (NCBI) Gene
Expression Omnibus (GEO) database and the European Bioinformatics Institute (EBI)
ArrayExpress database. Two studies from NCBI GEO database and one study from EBI
ArrayExpress were chosen for analysis based on the following characteristics:
1. Study used kidney tissue samples.
2. Insulin resistance and at least two other symptoms of metabolic syndrome were evident
in all rat models at the time of data collection.
3. All studies were single channel Affymetrix microarrays so that they could be easily
compared to investigate the entire rat genome.
4. Raw data was available online.
The raw microarray data was obtained via NCBI’s GEO2R or ArrayExpress and extracted
into a comma-separated values (.csv) file. This format of the data was compatible for statistical
analysis using the program R, and Microsoft Excel.

Studies Chosen for Analysis
After a thorough search for studies meeting the above criteria was performed, three studies were
selected for use in the meta-analysis. All three studies used an Affymetrix Rat Genome 230 2.0
One-Channel Array. All three studies also investigated a total of 31099 genes via microarrays.
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Table 2. Descriptions of the studies chosen for meta-analysis.

Study

Access
Number

Length of
Treatment

Rats Used

1

GSE4800

Started at
5 wks, fed
for 8 wks

13 wk old
male DS
rats and
Lewis rats

2

GSE7193

12 wks

3

E-MEXP1695

6 months

12 wk old
male ZO
rats and ZL
rats
BN rats
and GotoKakizaki
rats

Criteria for Relation
To Metabolic
Syndrome (in
addition to insulin
resistance
High triglyceride
levels, high blood
pressure, and a high
fasting blood
glucose level
Large waistline,
high blood pressure,
and a high fasting
blood glucose level
High triglyceride
levels, high blood
pressure, and a high
fasting blood
glucose level

Number of
Arrays Used

Link to Microarray Data

6 (3 Lewis, 3
DS)

http://www.ncbi.nlm.nih.go
v/geo/query/acc.cgi?acc=GS
E4800

6 (3 ZL
control diet, 3
ZO control
diet)
11 (5 normal
BN control, 6
Goto-Kakizaki
insulin
resistant)

http://www.ncbi.nlm.nih.go
v/geo/query/acc.cgi?acc=GS
E7193
http://www.ebi.ac.uk/arraye
xpress/experiments/EMEXP-1695

Study One: Dahl Salt-Sensitive Rats in Hypertension Study
Study one performed by (Yasui, Kajimoto, Sumiya, Okuda, & Iwai, 2007), used 13-week old
male Lewis rats and 13-week old male Dahl Salt-Sensitive (DS) fed a high salt diet (8% NaCl) in
order to study salt-sensitive hypertension. Male DS rats and Lewis rats were fed the high salt
diet starting at 5 weeks of age, and the treatment continued for 8 weeks. The DS rats were fed a
high salt diet to induce salt-sensitive hypertension. Their goal was to narrow down the genes
that may be involved in salt-sensitive hypertension in the kidney in the chromosome 10
quantitative trait loci region. Their control group in the microarray analysis included the Lewis
rats on a high salt diet, compared to the treatment rats (DS rats on a high salt diet). The
treatment rats developed the following three metabolic syndrome criteria: high triglyceride level,
high blood pressure, and a high fasting blood glucose level (Table 2). They did two other
microarray experiments; the data of which is available via GSE 4800. They selected genes that
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modulated expression more than 2-fold or less than 0.5 fold in all three of their studies. They
determined that 8 genes were differentially expressed by their criteria.
After reverse transcription, PCR verification, and Northern blot analysis, it was
determined that the expression levels of Ccl2 mRNA were 10-fold higher in the DS rats fed a
high salt diet than in the Lewis rats fed a high salt diet. This was the only gene whose trend was
verified via PCR, showing that it was differentially expressed between DS and Lewis rats after a
high salt diet, concluding that the gene is upregulated in the DS rats in response to a high salt
diet. Ccl2 is known to be involved in renal injury, and higher expression of Ccl2 could
aggravate macrophage infiltration, which can ultimately result in an exacerbation of saltsensitive hypertension. They concluded that this gene may be playing an influential role in
hypertension in the kidneys.
Why is this study applicable to this meta-analysis? For our study, the DS rats on a high
salt diet were used as the treatment and the Lewis rats fed a high salt diet were the control. A
total of 6 arrays were used from this study (3 DS arrays, and 3 Lewis arrays). This study uses
Dahl-Salt sensitive rats, which by definition exhibit hypertension, insulin resistance,
hyperinsulinemia, and hypertriglyceridemia (Animal models of disease: Metabolic, renal, and
cardiovascular.2011). Although this study focuses on studying hypertension, the characteristics
these rats exhibit fit our criteria for a diagnosis of MetS, making it an applicable study to include
in the meta-analysis.
Study Two: Zucker Obese Rat Study
The study by (Song, Liu, Ressom, Tiwari, & Ecelbarger, 2008) used 12-week old male Zucker
Lean (ZL) rats as the control rat and 12-week-old male Zucker Obese (ZO) rats as the treatment
rat in an experiment studying obesity as it related to the development of type 2 diabetes. Zucker
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Obese rats have a deletion mutation in the leptin receptor, which causes misregulation of appetite
and hunger. These rats develop a large waistline, high blood pressure, and a high fasting blood
glucose level (Table 2). In addition to studying the difference in gene expression between ZO
and ZL rats, the study also examines the effects of different compounds used as potential
diabetes drugs, such as rosiglitazone and thiazolidinediones.
Using the microarray data, 903 probe sets were determined to be significantly altered
with at least a 1.5-fold change between the control and treatment groups. There were 300 probe
sets that were increased and 244 probe sets that were decreased in obese rats compared to lean
rats. Increased genes included the B-subunit of the epithelial sodium channel (ENaC), the
thiazide-sensitive Na-Cl cotransporter, and aquaporin 3. Decreased genes included angiotensinconverting enzyme, type 1 (ACE1) (Song et al., 2008).
Why is this study applicable to this meta-analysis? For our study, 3 arrays from the ZO
rats and 3 arrays from the ZL rats were used as the treatment and control respectively. Zucker
Obese rats were used to study obesity and T2DM. Zucker rats by definition have the following
characteristics: obesity, insulin resistance, hyperinsulinemia, and hypertriglyceridemia (Harlan
Laboratories, 2014). Although this study focused on the effects of obesity and diabetes, it is
useful for this meta-analysis since the Zucker Diabetic Fatty (ZDF) rats used for PCR
verification are also obese and diabetic.
Study Three: Insulin Resistance in a Transgenic Rat Strain
In a study by (Wallis et al., 2008) the cardio-metabolic syndrome (similar to our definition of
metabolic syndrome) was examined using Brown Norway (BN) rats as the control rats and GotoKakizaki (BN.GK-D1Wox18/D1Got254, a transgenic insulin resistant strain) rats as the
treatment rats. This study utilizes this type of rat to examine genes related to diabetes and
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obesity, because GK rats carry a mutation in a G-protein receptor that is primarily associated
with obesity. These rats exhibit high triglyceride levels, high blood pressure, and a high fasting
blood glucose level (Table 2).
At the 12 and 24 week stage the congenic rats showed elevated blood glucose levels and
hyperinsulinemia. Six-month-old rats were used for microarray analysis. According to the
microarray data, a significant difference in transcription was observed for 478 distinct genes, and
the trends were verified for 38 of the genes. The results of this study identified a genetic basis of
risk factors for the cardio-metabolic syndrome.
Why is this study applicable to this meta-analysis? This study uses Goto-Kakizaki rats to
investigate the cardio-metabolic syndrome. Goto-Kakizaki rats naturally develop T2DM early in
life, but they are not obese. These rats are commonly used in studies investigating metabolic
phenomena, and again meet our criteria for having metabolic syndrome. Since T2DM is a
common result of MetS, this study adds to our meta-analysis with regards to the later stages of
MetS.
Pre-Processing of Data
The data was processed by a previous group of students involved in the Undergraduate Research
in Biology and Mathematics (UBM) program (Lauren van Reesema, Keith Zirkle, and Jonah
Williams) and Dr. Nusrat Jahan. The raw data in its entirety was extracted from either the NCBI
GEO Omnibus database or EBI ArrayExpress and converted into .csv files for later use with
Microsoft Excel and the program R for statistical analysis. For each of the three studies, separate
.csv files were generated for the specified wild type and treatment data.
The resulting data was then quantile normalized before it was individually analyzed via
the program R. Quantile normalization is performed so that all of the arrays have the same
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distribution, shape and similar spread. Next, for each gene, a t-test was performed to determine
individual significant differences in gene expression. This analysis resulted in a test statistic to
account for study variation and a p-value for each gene.
The statistical program R is used for analysis of microarray data. Before any statistical
analysis can be performed, the data were pre-processed. The pre-processing included averaging
gene duplicate values, log-2 base transformation and quantile normalization of the data. The
original data are right skewed, but all statistical tests require data to have at least approximately
normal distribution. Log transformation is a technique that makes right skewed distribution
more symmetric by minimizing the scale of differences between values. With this technique, if
the gene signal intensity is very similar between the treatment and the control, the treatment to
control ratio will be close to one, and the log2(1) is equal to 0. If the treatment signal intensity is
larger than the control, the ratio will be greater than one and log transformation will produce a
positive number, signaling an upregulated gene. On the other hand, if treatment signal intensity
is smaller than the control intensity, a negative number will result signaling a downregulated
gene.
Mean log(gene expression) = Mean log(treatment expression) – Mean log(wild-type expression)

Meta-Analysis
The meta-analysis performed in this project was performed by Dr. Jahan, using the program R
and a code presented in Appendix 1. An effect size (u) was calculated for each gene using the
following formula, where ym is the mean treatment gene expression of the gene m, and xm is the
mean gene expression of the wild-type:
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The effect size represents the standardized mean difference in gene expression for the
treatment and wild-type rats. The mean gene expression of the control is subtracted from the
mean treatment gene expression. This is then divided by the pooled standard deviation and a
correction factor (sipool). Using a pooled standard deviation accounts for the variability in the
three studies and standardizes the sample sizes of the studies. The correction factor is used to
ensure that the denominator is large enough to not artificially inflate the meta-Z value. The
correction factor used is the 90th percentile point.
The meta-Z statistic is calculated for each gene using the mean and variance. The mean
is divided by the square root of the variance. The purpose of the meta-Z value is to determine
the threshold value for significant genes corresponding to a specified quantile or cut off point
(Hu, Greenwood, & Beyene, 2005). The meta-Z values were then used to determine the
statistical significance of each gene.
Determination of Significant Genes within the Meta-Analysis
Genes were considered to be significantly upregulated if the meta-Z score was greater than or
equal to +1.8888 and were considered to be downregulated if the meta-Z score was less than or
equal to -2.054. These meta-Z cut off values were assigned stringently in order to minimize the
presence of false positives and negatives. In order to determine the meta-Z cut offs, the
difference between the meta-Z and the perm-Zs (permuted meta-Zs) were taken into account.
Meta-Z cutoff values of 1.8888 and -2.054 were found using a difference of 2 between the true
meta-Z and the average of the permuted meta-Z. The perm-Zs are calculated in the same way
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that the meta-Zs are calculated, but used the random permutation of the original data.
Permutation is described further in the next paragraph with regards to the false discovery rate. If
a gene is not different between the treatment and control, then the random permutation of the
data will produce perm-Z values that would be very different from the meta-Z values (Hu et al.,
2005). If a gene is significant based on permutation, it can be concluded that the gene is not
significantly different between the treatment and wild-type samples and its significance in the
permuted data is purely due to random chance.
The false discovery rate (FDR) method can be used to control the amount of false
positive genes in the data set. The FDR is determined by dividing the number of expected false
positive genes by the number of truly significant genes. The number of truly significant genes
must be estimated since it is unknown. This means that the FDR is also estimated using a
permutation method. This method is described by (Tusher, Tibshirani, & Chu, 2001).
Permuting the data rearranges it to account for every possible scenario of gene expression. A
weighted average, weighted variance, and a meta-Z statistic are generated for each gene in each
permutation. Since the data is permuted β times, there are β permuted meta-Zs for each gene.
The permuted meta-Z values are arranged from smallest to largest within each permutation and
using the same threshold quantile that is used to identify significant genes from the meta-Zs,
significant genes can be determined within each permutation. These significant genes represent
the false positives, since the permuted data should not have differential effects.
In cases where gene expression is inaccurately reported as significantly different, a type 1
(false positive) error occurs (Storey & Tibshirani, 2003). Although in most statistical tests a
significance level of 0.05 is used to determine the error rate, in microarray studies an alternate
method must be used due to the large amount of genes being tested at once. Since approximately
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30,000 genes are being tested simultaneously, the error rate of each gene is combined producing
an overall large error rate. For example, when testing 30,000 genes each with an error rate of
0.05, there would be 1,500 expected false positives. This error rate is way too large for the study
to have any statistical significance and relevance.
Quality Check of Significant Genes
In order for genes to truly be considered significantly upregulated or significantly
downregulated, some additional parameters were put in place to ensure that these significant
genes made biological sense. The first criterion was that the average fold change for all three
studies was at least a 1.5 fold difference between the treatment animals and the wild-type
animals. This was used in order to determine whether or not the genes were biologically
significant, using the following equation:
log2(1.5) = 0.58496
This means that the average fold change of significant genes must be ≥ 0.58496 or ≤ -0.58496.
The second criterion was that for a gene to be deemed upregulated, it must have a fold change ≥
0.58496 in at least two of the three studies, and must have a positive fold change in the third
study. For a gene to be deemed downregulated, it must have a fold change ≤ -0.58496 in at least
two of the three studies, and must have a negative fold change in the third study. This ensures
that the average fold change is not artificially inflated or deflated based on a particular study.
There are many possible scenarios that can be considered in regards to the previously described
criteria. For example, a gene could be really highly upregulated in one study, but not quite
upregulated enough in the other two studies to be statistically significant. Since the first study is
inflating the average expression of the gene, this gene would not be retained in the list of genes
to further investigate since it does not meet our criteria that a gene must be significant in at least
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2 of the three studies and follow the general trend for gene expression in the third study.
Another case could be that a gene is highly upregulated in two of the studies, but downregulated
in the third study. This gene would also not be included in the list of genes to analyze further
since it does not meet the specified criteria.
For example, the gene titled Syt10 (synaptotagmin X) meets our statistical cutoff value
for the meta-z statistic to be called statistically significant and has an overall gene expression of
1.5 fold for all three studies, as seen by its average fold change of 0.808. The fold change for
study one is 0.877, and the fold change for study two is 1.309. These positive values (>0.58)
support the conclusion that this gene is upregulated. However, the fold change for study three is
0.239, which still shows a slight upregulation, but not enough to meet our criteria of 0.58 (0.239
< 0.58). Since all three studies agree at this basic biologic level (upregulation) even though the
third does not, it will be retained in the list of genes for further examination.
To carry out this screening, any gene with a fold change < 0.58496 or > -0.58496 was
flagged in study one. Then, any gene with a fold change < 0.58496 or > -0.58496 and was
flagged in study two. If it had been flagged in both studies one and two, it was entirely ruled out
because it did not meet our criteria (since it would be out in two of the three studies). The same
criteria were used for study three. Again, if it was < 0.58496 or > -0.58496 it was flagged, and if
it had been previously flagged in either study one or study two (or both studies) it was ruled out
overall.
Next, some genes were thrown off simply because we were unable to determine their
biological function. Lastly, genes that had already been associated with metabolic syndrome
were excluded from analysis, since this thesis aims to find novel genes that could be influential
in the pathology of metabolic syndrome.
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Tissue Extraction
In order to verify the gene expression changes in these novel genes, tissues were obtained from
Zucker Diabetic Fatty rats fed a 66% fructose diet or a standard diet for 10 weeks while
monitoring their blood glucose and insulin levels. Zucker Diabetic Fatty rats exhibit type 2diabetes, hyperlipidemia, glucose intolerance, obesity, and hyperinsulinemia (Animal models of
disease: Metabolic, renal, and cardiovascular.2011). The rats were characterized as diabetic at
the time of tissue extraction by their marked hyperglycemia and hyperinsulinemia. Kidney tissue
was harvested by Divya Bansal, a former graduate student in the lab. These tissues were
surgically removed and stored in 3-4 mL of RNA later® solution to inhibit RNase activity. The
tissues were stored in this solution for two days at 4°C, then transferred to a new tube and stored
at -80°C until use.
RNA Isolation
To study gene expression, RNA was isolated from the kidney tissue by Divya Bansal using the
TRIzol method. Four basic steps were used in the process of RNA isolation: breaking open the
kidney cells, preparing the RNA, determining the concentration of the prepared RNA, and
checking the RNA for degradation using gel electrophoresis. Throughout this process, care was
taken to avoid RNase activity by using RNAZap (Ambion) detergent wipes to chemically treat
everything that could have potentially come in contact with the sample.
To homogenize the kidney tissue, approximately 500 µL of TRIzol reagent per 50-100
mg of tissue was added to a dounce homogenizer in order to lyse kidney cells. The kidney
sample was dissolved in the TRIzol reagent as quickly as possible to prevent degradation of the
sample by RNases.
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After homogenization, the sample was moved to a RNase free 15 mL tube and incubated
at room temperature for 5 minutes. Approximately 200 mL of chloroform per one mL of TRIzol
reagent was added to the tube and shaken vigorously for 20 seconds. This mixture was
incubated at room temperature for an additional 5 minutes. Centrifugation at 12,000 × G at 4°C
for 15 minutes was used to pellet the cells by dividing the hydrophilic RNA from the
hydrophobic proteins and bulkier DNA. The upper aqueous clear layer contains the RNA and
was placed in a new tube with 500 mL of isopropanol per one mL of TRIzol reagent used to
precipitate the RNA. This tube was vortexed and incubated at room temperature for 5 minutes,
then centrifuged at 12,000 × G at 4°C for 8 minutes. The supernatant was poured off, and one
mL of 75% ethanol per one mL of TRIzol reagent was added to the pellet. The sample was then
centrifuged at 7,500 × G at 4°C, and the ethanol was poured off. To remove the remaining
ethanol, the sample was centrifuged again for one minute and the remaining ethanol was pipetted
off. The sample was then dried in the fume hood for approximately 5 minutes to allow the
remaining ethanol to evaporate. Once the samples were dried the RNA was resuspended in 50
µL of RNA Storage Solution and stored at -80°C.
Examining the Quality of the RNA
To quantify the isolated RNA, the Nano-vue spectrophotometer was used to measure the
absorbance of the sample at 260 nm (A260) and 280 nm (A280), and determine the concentration
of the isolated RNA. The quality of the RNA was determined using a ratio (A260/A280), which
represents the ratio of nucleotide absorbance and protein absorbance. Pure RNA should have a
A260/A280 of 2.0-2.2, but any ratio over 1.9 was considered acceptable RNA quality.
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To ensure the RNA quality, the RNA was run on a 1.2% agarose gel. Two distinct bands
are shown for good quality RNA: a 28S band and a 18S band. These represent the large and
small subunits of ribosomal RNA. The 28s band appears twice as bright as the 18S band.

Reverse Transcription of RNA
Once the RNA was deemed to have adequate quality, it was reversed transcribed from RNA into
cDNA using a Superscript II Invitrogen kit. A mixture of 5 µg of RNA, 2 µL of random
hexamers, 1 µL of dNTPs, and nuclease free water was added together to make a total volume of
10 µL. The sample was then incubated at 70 °C for five minutes, and placed on ice for one
minute to denature the RNA and primers. Next, a mixture of 2 µL of 10x RT buffer, 2 µL of 0.1
M DTT, 2 µL of 50 mM MgCl2, and 1 µL of RNase out inhibitor was added and the sample was
incubated for two minutes. Next, 0.5 µL of 50 units/µL Superscript II RT was added to the
sample, which was then incubated at 42°C for 50 minutes. Lastly, 0.5 µL of 100 units/µL RNase
H was added to the sample, which was then incubated at 37°C for 30 minutes. The samples were
then stored at -20 °C until quantitative real-time PCR could be performed.

Primer Design
In order to verify the gene expression of the chosen novel genes, primers specific to each gene
had to be designed. The NCBI Primer Blast program was used to accomplish this
(http://www.ncbi.nlm.nih.gov/tools/primer-blast/index.cgi?LINK_LOC=BlastHome). The
mRNA sequence was located and entered into the program. The following parameters were
changed from the defaults: PCR product size (70-300 bp) and melting temperature (57° C - 63°
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C, with optimal melting temperature at 60° C). The returned forward and reverse primer
sequences were checked to make sure that they spanned at least one intron, and that the
sequences did not match anything else in the genome besides the gene being amplified.

Table 3. Primer sets used in qPCR.

Product Name

Sequence

B-actin Fwd
B-actin Rev
Mgmt Fwd
Mgmt Rev
Ampd3 Fwd
Ampd3 Rev
Klk1c9 Fwd
Klk1c9 Rev
Stk32c Fwd
Stk32c Rev
RGD 1309350 Fwd
RGD 1309350 Rev

5’-AAC CCT AAG GCC AAC CGT GAA AAG-3’
5’-TCA TGA GGT AGT CTG TCA GGT-3’
5’-GTG AGC GAG GCG TGC ATG GG-3’
5’- CCCACCGAGCACCTCAGGAC-3’
5’- ACCAACGCTTGCTGGTCGGT-3’
5’- TCTCTGCCAACAGCCGGACA-3’
5’- CCTGTTCCTCGCCCTGTCCCT-3’
5’- ATCAGGACACCCCCGCAGAAAG-3’
5’- CCGCGGGCTCCGATGTGTC-3’
5’- GCTTCTGCACGATGCACACCT-3’
5’-GCCTACGTTTGTGCCGCCTG-3’
5’-GTAGCGCTCCGTGTCGAAGG-3’

Product
Length
241 bp
95 bp
105 bp
144 bp
264 bp
152 bp

Figure 4 shows a DNA gel of the primers sepcified above. A one kilobase ladder was
used, and 12 µL (including 6X loading dye) of each primer solution was loaded in each well.

Figure 4. Gel showing the 5 primers and the housekeeping gene (B-actin). In lane one, Ampd3 was run. Lane 2
contains B-actin. Lane 3 contains Klk1c9. Lane 4 contains Mgmt, Lane 5 contains the molecular weight marker.
Lane 6 contains RGD 1309350. Lane 7 contains Stk32c.
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Quantitative Real-Time Polymerase Chain Reaction
To amplify DNA containing the genes of interest and B-actin, quantitative real-time polymerase
chain reaction (qPCR) was used. A fluorescent dye called SYBR green is used to identify
double-stranded DNA, thus inducing a brighter fluorescence as amplification continues.
To perform qPCR on the various samples, a master mix containing 1X SYBR green
(enzymes and a dye that fits between double stranded DNA), and 0.2 µM forward and reverse
primers for B-actin, Mgmt, Ampd3, Klk1c9, RGD1309350, or Stk32c was made. The various
primer sets used are presented in Table 3. For each reaction, components were added in the
following proportions: 10 µL of SYBR green master mix, 2 µL of 2mM primer, 2 uL of cDNA
and 6 uL of water totaling 20 uL for each reaction. Each gene was amplified with its specific
primer for each of the three control samples, and each of the 4 treatment samples. The reactions
were then run on a Bio Rad Opticon Monitor CFX96 Touch™ Real-Time PCR Detection System
(185-5196) with the following cycling conditions: 50°C for 2 minutes, 90°C for 2 minutes to
denature cDNA and activate enzymes, followed by 50 cycles of: 95°C for 15 seconds, 60°C for
30 seconds, with a plate read at 60°C, which was used to analyze the data in regression mode.
After the 50 cycles, the temperature was lowered to 60°C for 10 minutes. The machine then
constructed a melting curve starting at 76°C, taking measurements every 0.2°C up to 98°C.
After the amplification was complete, the products were run on a 2% agarose gel to confirm that
the correct cDNA fragments were amplified (Figure 4).
Data Analysis For Determining Gene Expression
Data was analyzed using the 2-

ΔΔ

C

T

method, or the Livak method. This method assumes that both

the target gene and the housekeeping gene are amplified with efficiencies near 100% and within
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5% of each other. First, normalization of the CT of the target gene and the housekeeping gene
was performed.
ΔCT(test)=CT(target,test)-CT(ref,test)
ΔCT(calibrator)=CT(target,calibrator)-CT(ref,calibrator)
Next the ΔCT of the test sample was normalized to the ΔCT of the calibrator:
ΔΔCT=ΔCT(test)- ΔCT(calibrator)
Last, the expression ratio was determined using the following equation:
2-

ΔΔ

C

T=Normalized

expression ratio

Once the normalized expression ratio is obtained, it is converted into a percentage. This
percentage is indicative of the percent of the control expression that the treatment is expressing.
For example, if the normalized expression ratio is 0.66, it can be concluded that the gene is
expressed at 66% of the control expression. This gene would be considered downregulated
because it is expressed 34% less in the treatment than it is in the control.

33

Results

To determine what genes may be influential in the pathology of metabolic syndrome, a metaanalysis of 3 microarray studies was performed. After running the R code presented in Appendix
1 and before screening for the significant genes, there were 12,328 genes in common in this
meta-analysis. Based on the meta-Z cutoffs of 1.8888 and -2.054, 597 genes were found to be
significant: 551 of these genes were upregulated, and 46 of the genes were downregulated.
After screening the genes to determine which ones had an average fold change for all
three studies that was at least a 1.5 fold difference between the treatment animals and the wildtype animals, 158 genes remained (this list of genes is available in the Appendix 2). Of the 158
genes, 135 were upregulated, and 23 were downregulated (Table 4). After screening the gene list
according to the fold change in study one, 18 of the 158 genes were flagged because they did not
have a fold change that was changed by 1.5 fold in study one. After screening the gene list
according to the fold change in study 2, 51 of the 158 genes were not changed by 1.5 fold in
study two (2 of which had already been flagged in study one). After screening the gene list
according to the fold change in study three, only 90 genes remained that were not “off” in two of
the studies.

Table 4. Genes meeting the criteria for an average fold change of > 0.58496 or < -0.58496.
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Genes With a Fold Change of 1.5-fold or Greater
Upregulated
Havcr1, Scg2, RGD1562844, Eps8l3, Pthlh, C4bpb, Socs2, Clcf1, Thsd7b,
Atpbd3, Kntc1, Fezf2, Gkn2, Clu, Hfe2, RGD1565709, Ckap2, Traf4af1,
Prl3d1, LOC500118, Tmsb10, Mfap5, Abra, Adamts1, Dscc1, Ctsw, Timp1,
Fcrls, Ttc25, Dfnb59, Dlgap5, Tnfrsf12a, Mgmt, RT1-Db1, Fetub,
LOC290595, Ltbp2, Ttk, Rbm11, Cox6a2, Tekt1, LOC691979, Mbnl3,
Clec2d, Pemt, Ccna2, Xkr4, Syt10, Ptgs2, C3, Prc1, Wtap, Mfap3,
RGD1561849, Kcne1, Krt25, Cd8a, Tekt5, Gpx7, Fes, Ccl2, Casp4, Apoa1,
Mpp3, RGD1563091, Arhgap11a, RGD1310862, Cox15, Mfap4, Lum,
LOC378467, Nkg7, P2rx4, Col8a1, Pqlc3, Ptprz1, Spp1, RGD1559980,
Sass6, Asns, Lsp1, Nipsnap3a, Eml2, S100b, Ubash3b, Slc18a1, Pmf1,
Mical1, Tap1, Trpv1, Slc15a3, LOC497995, Depdc1, Fgb, Rftn2, Rrm2, Gda,
LOC654482, Psmb9, Dclk1, Samsn1, Tdrd1, RGD1311558, Rab19, Kcnip3,
Bin2a, Pcp4l1, RGD1305713, Cds2, Grem1, Pycard, Itih1, Bub1, Jrk, Col3a1,
Athl1, Ccl20, Cmtm3, Slc7a7, LOC503175, RGD1565844, Cebpa,
RGD1307621, C1qb, Ampd3, Actn3, Ccdc80, Cxcl10, Obfc2a, Fgr, Agap2,
Lgals3bp, Tmed6, Hck, Cks2

Downregulated
Abcb11, Rnf40, F2, Snap25,
Bmp15, F5, Apoc1, Nell1,
Mlc1, Serpinc1, Cep78, Grhl3,
Krt14, Rp1h, Rbp4, Mrgprg,
Scgb1c1, Slc22a13,
RGD1309350, Hsd3b6, Klks3,
Stk32c, Cyp2c

After removing genes that we were unable to determine their biological function, there
were a total of 88 genes (73 were upregulated and 15 were downregulated) (Table 5). Lastly,
after genes that had already been associated with metabolic syndrome were excluded from
analysis 51 genes remained. A total of 37 out of the total 88 genes used for analysis had already
been associated with MetS in the literature (Table 5). This means that 42.0% of the significant
genes had already been associated with MetS. The 51 novel genes can be seen in Table 5.
Table 5. Genes already associated with MetS, and remaining novel genes. Remaining novel genes refers to their
novelty to MetS association, not novelty in function.

Genes Already Associated with MetS
Hfe2, Havcr1, Spp1, Athl1, Rrm2,
Kcnip3, Ccl2, C1qb, Pthlh,
Tnfrsf12a, RGD1563091, Ccl20,
Socs2, C4bpb, RT1-Db1, Timp1,
Fes, Tap1, Serpinc1, Hsd3b6,
Snap25, Mlc1, Mfap5, Psmb9,
Ltbp2, Col8a1, Lum, Grem1, Ptgs2,
Clcf1, Ccna2, Clu, Abcb11, Rbp4,
Cyp2c, Rp1h, Pemt

Remaining Novel Genes
Abra, Ampd3, Arhgap11a, Atpbd3, Casp4, Ccdc80,
Cep78, Ckap2, Cmtm3, Dclk1, Dscc1, Eml2, Eps8l3,
Fetub, Gkn2, Grhl3, Jrk, Klk1c9, Kntc1, Krt25,
Lgals3bp, LOC500118, LOC654482, Mgmt, Mrgprg,
Nell1, Nipsnap3a, Pcp4l1, Pmf1, Pqlc3, Prc1, Prl3d1,
Ptprz1, Rab19, Rbm11, Rftn2, RGD1307621,
RGD1309350, RGD1311558, RGD1562844,
RGD1565709, Sass6, Scg2, Scgb1c1, Slc15a3, Stk32c,
Syt10, Tmsb10, Traf4af1, Ttk, Xkr4

35

Five genes were chosen as novel genes in relation to MetS that will be investigated
further. The five chosen genes are: Ampd3, Klk1c9, Mgmt, RGD1309350, Stk32c. These genes
were chosen based on their role in metabolism. A majority of the genes can be classified as
having to do with an amino acid’s role in metabolism or DNA packaging. Some genes were
simply chosen for their statistical characteristics. RGD1309350, Klk1c9, and Stk32c are
expected to be downregulated and Ampd3, and Mgmt are expected to be upregulated (Table 8).
Preliminary PCR data and subsequent analysis using the Livak method described in the
Methods is shown in Table 6. The values in the table represent the percentage of the treatment
compared to the control. For example, a value of 0.66128 means that the treatment’s gene
expression is 66.128% of the controls gene expression, and thus will be considered
downregulated.
Table 6. Gene expression of treatment samples depicted as a percentage of the control.

Primer
Treatment 1
Treatment 2
Treatment 3
Treatment 4

Ampd3
66.128 %
74.9154 %
86.9545 %
0.006746 %

Klk1c9
122.0171 %
103.6761 %
67.6932 %
2.0152 %

Mgmt
217.8472 %
317.8472 %
710.2532 %
38.1124 %

RGD1309350
57.4349 %
2208.508 %
46.6516 %
1.8136 %

Stk32c
464.8719 %
516.7023 %
36.7122 %
2.0751 %

If the four treatments are averaged, the average gene expression can be obtained and used
to determine whether the gene is upregulated or downregulated. The average gene expressions
are as follows: Ampd3 is 0.571681, Klk1c9 is 0.738504, Mgmt is 3.210156, RGD1309350 is
5.78602, and Stk32c is 2.550904 (Table 7).
Table 7. Average gene expression ± a standard deviation.

Primer
Average

Ampd3
57.168 ± 38.6 %

Klk1c9
73.850 ± 52.9 %

Mgmt
321.016 ± 284.1
%
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RGD1309350
578.602 ± 1086.9
%

Stk32c
255.090 ± 273.3 %

Table 8. Information used for the five chosen genes.

Gene

Expected Gene
Expression

Average Fold
Change

Ampd3

upregulated

0.608

Fold Changes For
Individual Studies
(1,2,3)
1.12, 0.61, 0.091

Klk1c9

downregulated

-1.436

-1.93, -2.16, -0.22

Mgmt

upregulated

0.880

RGD1309350

downregulated

-1.241

Stk32c

downregulated

-1.948

37

Meta-Z
2.78
-3.48

0.87, 0.60, 1.17

3.31

-1.44, -1.68, -0.60

-4.16

-3.85, -0.072, -1.92

-2.96

PCR
verification
57.17 %
73.85 %
321.02 %
578.60 %
255.09 %

Discussion

The complex nature of metabolic syndrome is multi-faceted, which has been influential in
increasing the amount of research and attention being devoted to this disorder. This thesis aims
to elucidate some of the factors that may be playing a role in its pathology by studying gene
expression. Overall, the purpose of this thesis is to determine what genes may be influential in
the development and progression of MetS in the kidney.
The purpose of using a meta-analysis to study the effect metabolic syndrome has on gene
expression is to gain statistical power. Since metabolic syndrome is a multi-factorial disease, a
meta-analysis is used to make a stronger and broader conclusion about the disease by examining
studies with different components of the disease. By combining the results of these studies, the
statistical power is increased which leads to a stronger conclusion about the regulation of gene
expression by metabolic syndrome. Due to limited amounts of available microarray data, not all
aspects of metabolic syndrome could be addressed in this thesis. However, since 37 out of 88
(42.0%) genes were already associated with metabolic syndrome, it seems that the methodology
used in this meta-analysis is valid.
When analyzing the data by fold change to ensure that the genes were actually
biologically significantly upregulated, the genes had to have significantly upregulated or
significantly downregulated fold changes in 2 of the 3 studies and follow the same trend in the
third study. When performing this step, many of the genes had significant fold changes in
studies one and two, but were thrown off in the third study. This could be due to the length of
diet treatment of the rats in the studies, with the third study treating the rats the longest. This
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could mean that the rats in that study were farther along in their progression of MetS, which
could differentially affect gene expression.
Although there are many advantages to using meta-analyses, there are also some
disadvantages. Due to the fact that different laboratories performed the different studies used in
the meta-analysis, it is possible that there is some variation in the protocols used for microarray
analysis. Other factors that could influence the accuracy of the meta-analysis include different
technologies, different techniques and/or accuracy of microarray hybridization, and differences
in the treatment of animals. Also, since the technique of a meta-analysis examines so many
genes at once (12,328 in this case), there is a possibility that genes are upregulated or
downregulated by random chance. Although we were stringent in the statistical analysis of this
data, the random chance present in this study could be influencing gene expression and thus
could be a source of error. Human error is of course a possibility in any experiment, and could
be contributing to the discontinuity of the data. These factors could account for some of the
inconsistencies observed in the data.
The trends in gene expression were verified in 2 of the 5 chosen genes via real-time PCR.
We used a fourth animal model for PCR verification. As mentioned in the Methods section, each
study used a different type of rat to examine gene expression. Our lab used Zucker Diabetic
Fatty rats to verify the gene expression observed in the meta-analysis, so the genetic differences
in the rats could be influential in their gene expression patterns.
Another topic worth noting is the role that hypertension could be playing in metabolic
syndrome. In this study, it is not considered as a separate factor that can occur in MetS, but
hypertension may actually have its own independent effects on kidney function, separate from
the effects triggered by metabolic syndrome. All of the rat models used in the three chosen
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studies exhibited high blood pressure, which show their link to hypertension. Since the rats used
for PCR verification were not hypertensive, the effects of gene expression in the kidney can be
soley attributed to metabolic syndrome pathogenesis, whereas in the studies used to gather the
microarray data this distinction cannot necessarily be made. The microarray studies could show
a bias towards the effects of hypertension on the kidneys since the rats used in all three studies
exhibited high blood pressure, whereas the Zucker Diabetic Fatty rats used for PCR verification
do not exhibit high blood pressure. Although the ZDF model was able to verify two genes from
the meta-analysis, there could be some false negatives in the PCR data resulting from the effects
of hypertension independently. Perhaps using a hypertensive diabetic rat model would ensure
that all influential genes are PCR verified.
The two genes that were verified are Klk1c9 and Mgmt. Klk1c9, Kallikrein 1-related
peptidase C9, encodes a protein that exhibits serine-type endopeptidase activity and is involved
in the positive regulation of vasoconstriction. Klk1c9 was significantly downregulated in studies
one and two, and followed the trend for downregulation in study three. Thus, this gene was
expected to be downregulated, which agrees with the PCR results that Klk1c9 was expressed at
73.850% of the control.
In a study by Yamamuro, rats exposed to a tickling stimulus had increased expression of
Klk1c9 and reduced amylase production (Yamamuro et al., 2013). The reduction of amylase by
submandibular glands could have implications for the digestion of carbohydrates, which links
this gene to metabolic dysfunction. According to the Rat Genome Database, this gene has also
been associated with cardiovascular disease. Since CVD is a common complication of MetS and
T2DM, this gene could be influential in the end-stage of MetS.
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Another study identified a broad chromosome 1 region around Klk1 that was influential
in regulating blood pressure levels. Since high blood pressure is one of the factors used to
denote MetS in our project, it is not surprising that this gene was verified as being downregulated
in the treatment rats compared to the control rats, which could mean that it is less active in
controlling blood pressure in rats with metabolic syndrome (Yasui et al., 2007).
O-6-methylguanine-DNA transferase (Mgmt) was significantly upregulated in all three
studies, which agrees with the preliminary PCR data that it is expressed 321.016 % of the control
in the treatment. Mgmt, which encodes a protein that exhibits calcium ion binding and
methylated-DNA-[protein]-cysteine S-methyltransferase activity. It is also involved in DNA
dealkylation and DNA repair (Laulederkind et al., 2013). DNA repair is an important step in
DNA replication, where mutations can be the cause of disease.
Mgmt could be influential in the pathology of MetS since obesity and metabolic
dysfunction have a founded genetic component. The Rat Genome Database also cites that Mgmt
is associated with neurologic disease. In many cases of MetS (especially those that evolve into
T2DM) patients experience peripheral neuropathy, which is loss of sensation caused by damage
to neurons. This links Mgmt to MetS since it is involved in DNA repair and neurologic disease,
which can occur in the pathology of MetS.
Although the remaining genes trends were not verified in PCR, some of them could
possibly still be contributing to metabolic syndrome pathogenesis. The general functions of the
unverified genes will be briefly discussed, to give some context as to why they were chosen for
this project.
Adenosine monophosphate deaminase 3 (Ampd3) was significantly upregulated in
studies one and two, and followed the general trend for upregulation in the third study, which
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was not supported by the PCR percentage of +/- 57.168 %. Ampd3 is a gene that encodes a
protein that exhibits AMP deaminase activity, and is involved in AMP catabolism. It also
participates in the purine metabolic pathway and has been previously associated with heart
disease and stroke (Laulederkind et al., 2013).
RGD1309350 (similar to transthyretin (4L369)) was significantly downregulated in all
three studies, but this was not supported by the PCR percentage of +/- 578.602 %. RGD1309350
encodes a protein that exhibits hydroxyisourate hydrolase activity and is involved in the purine
nucleobase metabolic process (Laulederkind et al., 2013). This gene was chosen for its possible
role in epigenetics.
Stk32c was significantly downregulated in studies one and three, and followed the trend
for downregulation in study two, which did not agree with the PCR percentage of +/- 255.090 %.
Stk32c encodes a protein that exhibits ATP binding and protein serine/threonine kinase activity
(Laulederkind et al., 2013). The phosphorylation step could be influential in signaling cascades
related to MetS. Stk32c was the most inconclusive gene with regards to the PCR data (gene
expression was greatly varied among the 4 treatments), suggesting a possible error with the
primer used for its amplification. Stk32c was expected to be downregulated, which disagrees
with the average PCR data, but further PCR analysis in necessary to confirm this finding.
Based on the discontinuity of the PCR data with the statistical expectations, future work
includes continuing to collect PCR data to verify the upregulation or downregulation trends.
This project could be expanded is by changing the definition used to define and diagnose
metabolic syndrome. Since the literature is so inconclusive as to the exact criteria needed to
diagnose a person with MetS, there may be some value in tweaking the criteria used to include
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studies in the meta-analysis. This could potentially result in more applicable studies that when
included in the meta-analysis, may uncover more novel genes to investigate.
Since the gene expression data is still preliminary, a much larger pool of data may be
necessary to verify the trends already observed through the PCR data. As future work reveals
more consistent PCR data, a more conclusive statement about the individual role of these genes
in the pathology of metabolic syndrome may provide influential insight into the etiology and
pathology of this increasingly prevalent disorder.
Overall, the importance of this study was to find novel genes that relate to the pathologic
effects of metabolic syndrome. Although preliminary PCR data was only able to verify the
trends in gene expression for two of the genes, these genes could be investigated even further
and eventually become the target of a new therapy or drug for metabolic syndrome or one of its
debilitating complications. This study serves as preliminary research into possible genes
involved in the pathogenesis of metabolic syndrome that can be continued in future work.
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Appendices

Appendix 1

R Code used in the meta-analysis:
#study1
study1<-read.csv("N:/UserG-L/jahannx/Diabetes/UBM
data/TransformedandMergedStudy1.csv",header=F,na.strings="NA")
head(study1)
tail(study1)
study2<-read.csv("N:/UserG-L/jahannx/Diabetes/UBM
data/TransformedandMergedStudy2.csv",header=F,na.strings="NA")
head(study2)
tail(study2)
study5<-read.csv("N:/UserG-L/jahannx/Diabetes/UBM
data/TransformedandMergedStudy5.csv",header=F,na.strings="NA")
head(study5)
tail(study5)
n<-length(study1[,1])
n
Gene.ID<-study1[,1]
Gene.Symbol<-study1[,2]
#this should match for IDs and symbols in all 3 merged studies (since they're sorted)
#log transformation
col3<-study1[,3];z1<-log(col3,2)
col4<-study1[,4];z2<-log(col4,2)
col5<-study1[,5];z3<-log(col5,2)
col6<-study1[,6];z4<-log(col6,2)
col7<-study1[,7];z5<-log(col7,2)
col8<-study1[,8];z6<-log(col8,2)
qnorm_w <-(1/3)*(sort(z1)+sort(z2)+sort(z3))
qw1<- qnorm_w[rank(z1)]; qw2<- qnorm_w[rank(z2)]; qw3<- qnorm_w[rank(z3)]
qnorm_m<-(1/3)*(sort(z4)+sort(z5)+sort(z6))
qm1<- qnorm_m[rank(z4)]; qm2<- qnorm_m[rank(z5)]; qm3<- qnorm_m[rank(z6)]
###***Quantile**Normalization**code************
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qw <- cbind(z1, z2,z3);qm<-cbind(z4,z5,z6)
qz1<-apply(apply(qw,2,sort),1,mean);qz2<-apply(apply(qm,2,sort),1,mean)
n<-length(qw[,1])
qzw<-matrix(rep(0,3*n),n,3)
for(i in 1:3){
qzw[,i]<-qz1[rank(qw[,i])]
}
qzm<-matrix(rep(0,3*n),n,3)
for(i in 1:3){
qzm[,i]<-qz2[rank(qm[,i])]
}
zzn1<-data.frame(qzw,qzm)
###****produces **same **normalized**data**as**above****
zzn1<- cbind(qw1,qw2,qw3,qm1,qm2,qm3)
head(zzn1)
###*****************************************************
# To use std dev correction proposed in SAM
se1<- sqrt(apply(zzn1,1,var)/6)
head(se1)
se11<- sort(se1)
s01<- quantile(se1,.90)
# To verify that 90th percentile is computed correctly
length(which (se11 > s01))
#m<-qzm
#w<-qzw
w<-zzn1[,1:3]; m<-zzn1[,4:6]
#get mean for each gene in mutant arrays
mean.m<-apply(m,1,mean)
#get mean for each gene in wild-type arrays
mean.w<-apply(w,1,mean)
#find difference between means for each gene
diff1<-mean.m-mean.w
#define how many mutant arrays
n.m=3
#define how many wild-type arrays
n.w=3
#get std. dev. for each gene in mutant arrays
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s.m<-apply(m,1,sd)
#get std. dev. for each gene in wild-type arrays
s.w<-apply(w,1,sd)
a<-(1/n.m + 1/n.w)/(n.m+n.w-2)
#gene specific scatter is computed
si1<- sqrt( a*((n.m-1)*s.m^2+(n.w-1)*s.w^2))
#gene relative difference between group means is computed (SAM method)
di1 <- diff1/(si1+s01)
#Weight for effect size meta-analysis
s1<-(1/n.m + 1/n.w + (di1)^2/(2*(n.m+n.w)))

#indiv1<-data.frame(Gene.Symbol, Gene.ID,qzw[,1],qzw[,2],qzw[,3],qzm[,1],qzm[,2],qzm[,3],
diff,di1, si1, s1)
indiv1<-data.frame(Gene.Symbol, Gene.ID,qw1,qw2,qw3,qm1,qm2,qm3, diff1,di1, si1, s1)
head(indiv1)

###############################
#study 2
study2<-read.csv("N:/UserG-L/jahannx/Diabetes/UBM
data/TransformedandMergedStudy2.csv",header=F,na.strings="NA")
head(study2)
Gene.ID<-study2[,1]
Gene.Symbol<-study2[,2]
#log transformation
col3<-study2[,3];z1<-log(col3,2)
col4<-study2[,4];z2<-log(col4,2)
col5<-study2[,5];z3<-log(col5,2)
col6<-study2[,6];z4<-log(col6,2)
col7<-study2[,7];z5<-log(col7,2)
col8<-study2[,8];z6<-log(col8,2)
qnorm_w <-(1/3)*(sort(z1)+sort(z2)+sort(z3))
qw1<- qnorm_w[rank(z1)]; qw2<- qnorm_w[rank(z2)]; qw3<- qnorm_w[rank(z3)]
qnorm_m<-(1/3)*(sort(z4)+sort(z5)+sort(z6))
qm1<- qnorm_m[rank(z4)]; qm2<- qnorm_m[rank(z5)]; qm3<- qnorm_m[rank(z6)]
#zzn2<- data.frame(qw1,qw2,qw3,qm1,qm2,qm3)
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zzn2<- cbind(qw1,qw2,qw3,qm1,qm2,qm3)
w<-zzn2[,1:3]; m<-zzn2[,4:6]
mean.m<-apply(m,1,mean)
mean.w<-apply(w,1,mean)
s.m<-apply(m,1,sd)
s.w<-apply(w,1,sd)
n.m<-3
n.w<-3
diff2<-mean.m-mean.w
a<-(1/n.m + 1/n.w)/(n.m+n.w-2)
#gene specific scatter is computed
si2<- sqrt( a*((n.m-1)*s.m^2+(n.w-1)*s.w^2))
# To use std dev correction proposed in SAM
se1<- sqrt(apply(zzn2,1,var)/6)
head(se1)
se11<- sort(se1)
s02<- quantile(se11,.90)
# To verify that 90th percentile is computed correctly
length(which (se11 > s02))

#gene relative difference between group means is computed (SAM method)
di2 <- diff2/(si2+s02)
#Weight for effect size meta-analysis
s2<-(1/n.m + 1/n.w + (di2)^2/(2*(n.m+n.w)))
indiv2<-data.frame(Gene.Symbol, Gene.ID,qw1,qw2,qw3,qm1,qm2,qm3, diff2,di2, si2, s2)
head(indiv2)
###############################
study5<-read.csv("N:/UserG-L/jahannx/Diabetes/UBM
data/TransformedandMergedStudy5.csv",header=F,na.strings="NA")
head(study5)
Gene.ID<-study5[,1]
Gene.Symbol<-study5[,2]
#log transformation was not needed
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col3<-study5[,3]
col4<-study5[,4]
col5<-study5[,5]
col6<-study5[,6]
col7<-study5[,7]
col8<-study5[,8]
col9<-study5[,9]
col10<-study5[,10]
col11<-study5[,11]
col12<-study5[,12]
zzn5<-cbind(col3,col4,col5,col6,col7,col8,col9,col10,col11,col12)
#specify groups
w<-zzn5[,1:4]; m<-zzn5[,5:10]
#get mean for each gene in mutant arrays
mean.m<-apply(m,1,mean)
#get mean for each gene in wild-type arrays
mean.w<-apply(w,1,mean)
#find difference between means for each gene
diff5<-mean.m-mean.w
#get std. dev. for each gene in mutant arrays
s.m<-apply(m,1,sd)
#get std. dev. for each gene in wild-type arrays
s.w<-apply(w,1,sd)
#define how many mutant arrays
n.m=6
#define how many wild-type arrays
n.w=4
# To use std dev correction proposed in SAM
se1<- sqrt(apply(zzn5,1,var)/(n.w+n.m))
head(se1)
se11<- sort(se1)
s05<- quantile(se11,.90)
# To verify that 90th percentile is computed correctly
length(which (se11 > s05))
a<-(1/n.m + 1/n.w)/(n.m+n.w-2)
#gene specific scatter is computed
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si5<- sqrt( a*((n.m-1)*s.m^2+(n.w-1)*s.w^2))
#gene relative difference between group menas is computed (SAM method)
di5 <- diff5/(si5+s05)
p=s05+si5[2]
diff5[2]/p
#Weight for effect size meta-analysis
s5<-(1/n.m + 1/n.w + (di5)^2/(2*(n.m+n.w)))
indiv5<-data.frame(Gene.Symbol, Gene.ID,col3,col4,col5,col6,col7,col8,col9,col10,col11,col12,
diff5,di5, si5, s5)
head(indiv5)

#########################################################################
all.new<-data.frame(Gene.Symbol,Gene.ID,diff1,di1,s1,diff2,di2,s2,diff5,di5,s5)

#write this data file into an Excel file for easy viewing
#write.csv(all.new,"N:/UserG-L/jahannx/Diabetes/UBM data/", row.names=T)
write.csv(all.new, file="allNew.csv")
getwd()
#Computing an average combined study effect size (meta-analysis effect size)
mu <- (di1*(1/s1) + di2*(1/s2)+di5*(1/s5))/(1/s1+1/s2+1/s5)
#Computing variance for the average combined study effect size
vmu <- (1/s1+1/s2+1/s5)/(1/s1+1/s2+1/s5)**2
#Computing meta z score
z0 <- mu/sqrt(vmu)
#Creating a file with meta-z's
meta.all<- data.frame(Gene.Symbol,Gene.ID,diff1,di1,diff2,di2,diff5,di5,z0)
write.csv(meta.all, file="metaAll.csv")
getwd()
meta.final<- data.frame(Gene.Symbol,Gene.ID,diff1,di1,diff2,di2,diff5,di5,z0, zdiff, zdiffabs)
write.csv(meta.final, file="meta.final.csv")
getwd()

plot(z0)
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plot(x <- sort(z0), type="s", title="Distribution of Meta-Zs")
################################################
#Different effect size standard error
################################################
s11 = (si1+s01)**2
s22 = (si2+s02)**2
s55 = (si5+s05)**2
#Computing an average combined study effect size (meta-analysis effect size)
mu.n <- (di1*(1/s11) + di2*(1/s22)+di5*(1/s55))/(1/s11+1/s22+1/s55)
#Computing variance for the average combined study effect size
vmu.n <- (1/s11+1/s22+1/s55)/(1/s11+1/s22+1/s55)**2
#Computing meta z score
z0.n <- mu.n/sqrt(vmu.n)
#Creating a file with meta-z's
meta.n<- data.frame(Gene.Symbol,Gene.ID,diff1,di1,s11,diff2,di2,s22,diff5,di5,s55,z0.n)
write.csv(meta.n, file="metaN.csv")
getwd()
#######################################################
#######################################################

#Starting permutation
w1<-1:n
muF<-1:n
muVar<-1:n
b<-1:n
mB<-1:n
B <- 100

for(j in 1:B)
{
x <- zzn1[,sample (ncol(zzn1))]
w <- x[, 1:3]
m <- x[, 4:6]
n.m=3
n.w=3
mean.w<-apply(w,1,mean)
s.w<-apply(w,1,sd)
mean.m<-apply(m,1,mean)
s.m<-apply(m,1,sd)
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a<-(1/n.m + 1/n.w)/(n.m+n.w-2)
#gene specific scatter is computed
sep<- sqrt( a*((n.m-1)*s.m^2+(n.w-1)*s.w^2))
se<- sqrt(apply(x,1,var)/6)
se0<- sort(se)
s01<- quantile(se0,.90)
size1 <- ((mean.m-mean.w)/(sep+s01))
s1<- (1/n.m + 1/n.w + size1^2/(2*n.m+2*n.w))

###########################################################
x <- zzn2[,sample (ncol(zzn2))]
w <- x[, 1:3]
m <- x[, 4:6]
n.m=3
n.w=3
mean.w<-apply(w,1,mean)
s.w<-apply(w,1,sd)
mean.m<-apply(m,1,mean)
s.m<-apply(m,1,sd)
a<-(1/n.m + 1/n.w)/(n.m+n.w-2)
#gene specific scatter is computed
sep<- sqrt( a*((n.m-1)*s.m^2+(n.w-1)*s.w^2))
se<- sqrt(apply(x,1,var)/6)
se0<- sort(se)
s0<- quantile(se0,.90)
size2 <- ((mean.m-mean.w)/(sep+s0))
s2<- (1/n.m + 1/n.w + size2^2/(2*n.m+2*n.w))
################################################################
x <- zzn5[,sample (ncol(zzn5))]
w <- x[, 1:4]
m <- x[, 5:10]
n.w=4
n.m=6
mean.w<-apply(w,1,mean)
s.w<-apply(w,1,sd)
mean.m<-apply(m,1,mean)
s.m<-apply(m,1,sd)
a<-(1/n.m + 1/n.w)/(n.m+n.w-2)
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#gene specific scatter is computed
sep<- sqrt( a*((n.m-1)*s.m^2+(n.w-1)*s.w^2))
se<- sqrt(apply(x,1,var)/10)
se0<- sort(se)
s0<- quantile(se0,.90)
size5 <- ((mean.m-mean.w)/(sep+s0))
s5<- (1/n.m + 1/n.w + size2^2/(2*n.m+2*n.w))
#########################################################################
all <- data.frame(Gene.ID, Gene.Symbol, size1,s1, size2, s2,size5, s5)
for(i in 1:n)
{
w1[i] <- sum(1/all[i,4]+ 1/all[i,6] + 1/all[i,8] )
muF[i]<- (sum(1/all[i,4]*all[i,3]+ 1/all[i,6]*all[i,5] + 1/all[i,8]*all[i,7] ))/w1[i]
muVar[i] <- w1[i]/(w1[i])^2
b[i]<-muF[i]/sqrt(muVar[i])
}
mB <- cbind(mB,b)
}
n1<-B+1
permZ<-data.frame(Gene.Symbol,Gene.ID,mB[,2:n1])
write.csv(permZ, file="permZ.csv")
getwd()

#write.csv(permZ,"/Users/keithwzirkle/Documents/UBM
DATA/100PermutedZ.csv",row.names=T)
#permZ<-read.csv("/Users/keithwzirkle/Documents/UBM DATA/100PermutedZ.csv")
zsum<-1:n
zbar<-1:n
zdiff<-1:n
zdiffabs<-1:n
for(i in 1:n)
{
zsum[i]<-sum(permZ[i,4:102],na.rm=T)
zbar[i]<-(1/B)*zsum[i]
zdiff[i]<-z0[i]-zbar[i]
zdiffabs[i]<-abs(zdiff[i])
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}
quantile(zdiff,.99,na.rm=T)
quantile(zdiff,.01,na.rm=T)

perm.Z<-permZ[,3:102]
count<- 1:n
for(i in 1:n){
count[i]<-0
for(j in 1:B){
if (abs(z0[i]) > abs(perm.Z[i,j]))
count[i] = count[i]+1
}
}
countRate = count/B
nm<-length(which(countRate[i]<=0.05))
count<-0
for(j in 1:B)
{
for(i in 1:n)
{
nm1<-length(which(perm.Z[i,]<=t2))
nm2<-length(which(perm.Z[i,]>=t1))
count<-count+nm1+nm2
}
}
n2<-B+2

nm<-count/B
fdr<-nm/dn
meta.final<- data.frame(Gene.Symbol,Gene.ID,diff1,di1,diff2,di2,diff5,di5,z0, zdiff, zdiffabs)
write.csv(meta.final, file="meta.final.csv")
getwd()
meta.B<- data.frame(Gene.Symbol,Gene.ID,z0,zbar,countRate)
write.csv(meta.B, file="meta.B.csv")
getwd()
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##############################################
#metaZs<-read.csv("/Users/keithwzirkle/Documents/UBM
DATA/MetaZs.csv",header=F,na.strings="NA")
#metaZ<-metaZs[,3]
metaZs<-read.csv("/Users/keithwzirkle/Documents/UBM DATA/MetaZs.csv")
#metaZ<-metaZs[,4]
#length(metaZ)
[1] 12329
#metaZ<-Z.ID[,3]
#quantile(metaZ,.999,na.rm=T)
#quantile(metaZ,.01)
t1<-(5.048028)
t2<-(-6.151412)
#t1<-quantile(z.diff,.995,na.rm=T);t2<-quantile(z.diff,.015,na.rm=T)
dn1<-length(which(metaZ<=t2))
dn2<-length(which(metaZ>=t1))
dn<-dn1+dn2
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Appendix 2
Gene >
Symbol

Gene >
Name

Gene > Description

Abcb11
Abra

actinbinding
Rho
activating
protein

Ampd3

adenosine
monopho
sphate
deaminas
e3

Apoc1

apolipopr
otein C-I

Arhgap
11a

Rho
GTPase
activating
protein
11A
ATH1
acid

Athl1

ENCODES a protein that exhibits actin binding
(ortholog) AND transcription coactivator activity
(ortholog) AND INVOLVED IN positive regulation of
Rho protein signal transduction (ortholog) AND positive
regulation of sequence-specific DNA binding
transcription factor activity (ortholog) AND positive
regulation of transcription from RNA polymerase II
promoter (ortholog) AND FOUND IN sarcomere AND
actin cytoskeleton (ortholog) AND myofibril (ortholog)
AND INTERACTS WITH C60 fullerene AND alltrans-retinoic acid AND ammonium chloride
ENCODES a protein that exhibits AMP deaminase
activity AND INVOLVED IN AMP catabolic process
(inferred) AND IMP biosynthetic process (inferred)
AND IMP salvage (inferred) AND PARTICIPATES IN
purine metabolic pathway AND ASSOCIATED WITH
Heart Diseases (ortholog) AND Muscular Diseases
(ortholog) AND Stroke (ortholog) AND INTERACTS
WITH DDE AND N-nitrosodiethylamine AND
ammonium acetate
ENCODES a protein that exhibits fatty acid binding
(ortholog) AND lipase inhibitor activity (ortholog) AND
phospholipase inhibitor activity (ortholog) AND
INVOLVED IN regulation of lipid transport AND
cholesterol efflux (ortholog) AND cholesterol metabolic
process (ortholog) AND PARTICIPATES IN altered
lipoprotein metabolic pathway AND lipoprotein
metabolic pathway AND ASSOCIATED WITH
Alzheimer Disease (ortholog) AND Carcinoma
Pancreatic Ductal (ortholog) AND Diabetes Mellitus
Type 2 (ortholog) AND FOUND IN high-density
lipoprotein particle AND very-low-density lipoprotein
particle AND endoplasmic reticulum (ortholog) AND
INTERACTS WITH 17alpha-ethynylestradiol AND 3methylcholanthrene AND alpha-hexachlorocyclohexane
INVOLVED IN signal transduction (inferred) AND
FOUND IN intracellular (inferred) AND INTERACTS
WITH sodium dichromate AND (-)-epigallocatechin 3gallate (ortholog) AND 2 3 7 8tetrachlorodibenzodioxine (ortholog)
ENCODES a protein that exhibits catalytic activity
(inferred) AND INVOLVED IN carbohydrate metabolic
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Average Fold
Change

Meta-Z
Statistic

-0.597781208

-2.710864478

0.980237889

1.89020657

0.608729665

2.781628136

-0.675625342

-2.420277079

0.731745946

2.227572701

0.624919691

3.390794405

Already
Associated
with MetS?
Yes

Yes

Yes

C1qb

trehalaselike 1
(yeast)
complem
ent
compone
nt 1 q
subcomp
onent B
chain

C4bpb

complem
ent
compone
nt 4
binding
protein
beta

Casp4

caspase 4
apoptosis
-related
cysteine
peptidase

Ccdc80

coiledcoil
domain
containin
g 80

Ccl2

chemokin
e (C-C
motif)
ligand 2

process (inferred) AND INTERACTS WITH 2 3 7 8tetrachlorodibenzodioxine (ortholog) AND paracetamol
(ortholog) AND propiconazole (ortholog)
ENCODES a protein that exhibits protein
homodimerization activity (ortholog) AND INVOLVED
IN aging AND brain development AND response to
glucocorticoid stimulus AND PARTICIPATES IN
Staphylococcus aureus infection pathway AND
Trypanosoma cruzi infection pathway AND coagulation
cascade pathway AND ASSOCIATED WITH Ocular
Hypertension AND Retrograde Degeneration AND
Spinal Cord Injuries AND FOUND IN complement
component C1 complex AND INTERACTS WITH 1 3dinitrobenzene AND 17alpha-ethynylestradiol AND 2 3
7 8-tetrachlorodibenzodioxine
INVOLVED IN complement activation classical
pathway (inferred) AND innate immune response
(inferred) AND PARTICIPATES IN forkhead class A
signaling pathway AND coagulation cascade pathway
AND complement system pathway AND FOUND IN
extracellular region (inferred) AND INTERACTS
WITH 2 3 7 8-tetrachlorodibenzodioxine AND 3H-1 2dithiole-3-thione AND N-nitrosodiethylamine
ENCODES a protein that exhibits scaffold protein
binding AND INVOLVED IN germ cell programmed
cell death (ortholog) AND FOUND IN neuron
projection AND neuronal cell body AND protein
complex AND INTERACTS WITH 1 1 1-trichloro-2 2bis(4-hydroxyphenyl)ethane AND 1 2 4trimethylbenzene AND 2 3 7 8tetrachlorodibenzodioxine
ENCODES a protein that exhibits fibronectin binding
(ortholog) AND glycosaminoglycan binding (ortholog)
AND heparin binding (ortholog) AND INVOLVED IN
extracellular matrix organization (ortholog) AND
positive regulation of cell-substrate adhesion (ortholog)
AND FOUND IN basement membrane (ortholog) AND
extracellular matrix (ortholog) AND interstitial matrix
(ortholog) AND INTERACTS WITH diuron AND
17alpha-ethynylestradiol (ortholog) AND 17betaestradiol (ortholog)
ENCODES a protein that exhibits CCR2 chemokine
receptor binding AND chemokine activity AND heparin
binding AND INVOLVED IN aging AND cellular
calcium ion homeostasis AND chemokine-mediated
signaling pathway AND PARTICIPATES IN
angiotensin II signaling pathway AND vascular
endothelial growth factor signaling pathway AND
granulocyte-macrophage colony-stimulating factor
signaling pathway AND ASSOCIATED WITH Acute
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Lung Injury AND Anti-Glomerular Basement
Membrane Disease AND Aortic Aneurysm Abdominal
AND FOUND IN cytoplasm AND extracellular space
AND neuronal cell body AND INTERACTS WITH ( )pilocarpine AND (3S 5R)-fluvastatin AND (S)colchicine
ENCODES a protein that exhibits chemokine activity
AND cytokine activity (ortholog) AND INVOLVED IN
chemokinesis AND PARTICIPATES IN chemokine
mediated signaling pathway AND cytokine mediated
signaling pathway AND rheumatoid arthritis pathway
AND FOUND IN extracellular space (inferred) AND
INTERACTS WITH 1 2 4-trimethylbenzene AND 2amino-2-deoxy-D-glucopyranose AND aldehydo-Dglucosamine
ENCODES a protein that exhibits protein kinase binding
(ortholog) AND INVOLVED IN organ regeneration
AND positive regulation of fibroblast proliferation AND
response to estradiol stimulus AND PARTICIPATES IN
p53 signaling pathway AND cell cycle pathway mitotic
AND ASSOCIATED WITH Carcinoma Embryonal
(ortholog) AND Heart Failure (ortholog) AND
Mammary Neoplasms Experimental (ortholog) AND
FOUND IN cytoplasm (ortholog) AND female
pronucleus (ortholog) AND male pronucleus (ortholog)
AND INTERACTS WITH 2 3 7 8tetrachlorodibenzodioxine AND 2-acetamidofluorene
AND 3 3' 4 4' 5-pentachlorobiphenyl
FOUND IN centrosome (ortholog) AND INTERACTS
WITH 2 4-dinitrotoluene AND 2 6-dinitrotoluene AND
ammonium chloride
INVOLVED IN mitotic cytokinesis (ortholog) AND
negative regulation of microtubule depolymerization
(ortholog) AND positive regulation of transcription from
RNA polymerase II promoter (ortholog) AND FOUND
IN centrosome (ortholog) AND cytoplasm (ortholog)
AND cytoplasmic microtubule (ortholog) AND
INTERACTS WITH 2-amino-2-deoxy-D-glucopyranose
AND aldehydo-D-glucosamine AND beta-Dglucosamine
ENCODES a protein that exhibits ciliary neurotrophic
factor receptor binding (ortholog) AND cytokine activity
(ortholog) AND protein heterodimerization activity
(ortholog) AND INVOLVED IN B cell differentiation
(ortholog) AND JAK-STAT cascade (ortholog) AND
cell surface receptor signaling pathway (ortholog) AND
PARTICIPATES IN Jak-Stat signaling pathway AND
cytokine mediated signaling pathway AND
ASSOCIATED WITH Cold-Induced Sweating
Syndrome 1 (ortholog) AND FOUND IN CNTFR-
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CLCF1 complex (ortholog) AND CRLF-CLCF1
complex (ortholog) AND extracellular region (ortholog)
AND INTERACTS WITH 2 4-dinitrotoluene AND 2 6dinitrotoluene AND C60 fullerene
ENCODES a protein that exhibits ATPase activity
(ortholog) AND misfolded protein binding (ortholog)
AND ubiquitin protein ligase binding (ortholog) AND
INVOLVED IN cellular response to growth factor
stimulus AND endocrine pancreas development AND
negative regulation of apoptotic process AND
ASSOCIATED WITH Brain Ischemia AND Ischemia
AND Arteriosclerosis (ortholog) AND FOUND IN
aggresome AND growth cone AND neuron projection
AND INTERACTS WITH 1-naphthyl isothiocyanate
AND 17alpha-ethynylestradiol AND 17beta-estradiol
FOUND IN integral to membrane (inferred) AND
INTERACTS WITH cisplatin AND 2 3 7 8tetrachlorodibenzodioxine (ortholog) AND
benzo[a]pyrene (ortholog)

INVOLVED IN camera-type eye morphogenesis
(ortholog) AND epithelial cell proliferation (ortholog)
AND positive regulation of cell-substrate adhesion
(ortholog) AND PARTICIPATES IN syndecan signaling
pathway AND FOUND IN extracellular matrix
(ortholog) AND INTERACTS WITH 2-amino-2-deoxyD-glucopyranose AND C60 fullerene AND aldehydoD-glucosamine
ENCODES a protein that exhibits tRNA binding
(ortholog) AND INVOLVED IN tRNA thiomodification (ortholog) AND tRNA wobble uridine
modification (ortholog) AND FOUND IN cytosol
(ortholog) AND mitochondrion (ortholog) AND
INTERACTS WITH 2 3 7 8-tetrachlorodibenzodioxine
(ortholog) AND benzo[a]pyrene (ortholog) AND
copper(2 ) sulfate (ortholog)
ENCODES a protein that exhibits chemokine activity
AND INVOLVED IN cellular response to heat AND
immune response AND negative regulation of
angiogenesis AND PARTICIPATES IN Retinoic acidinducible gene (RIG) I-like receptor signaling pathway
AND Toll-like receptor signaling pathway AND
chemokine mediated signaling pathway AND
ASSOCIATED WITH Brain Ischemia AND
Bronchiolitis Viral AND Diabetes Mellitus Type 1
AND FOUND IN extracellular space AND external side
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of plasma membrane (ortholog) AND extracellular
region (ortholog) AND INTERACTS WITH 2 3 7 8tetrachlorodibenzodioxine AND 2 4 6-trinitrotoluene
AND 2 4-dinitrotoluene
ENCODES a protein that exhibits testosterone 16-alphahydroxylase activity AND caffeine oxidase activity
(ortholog) AND drug binding (ortholog) AND
INVOLVED IN cellular amide metabolic process
(ortholog) AND drug catabolic process (ortholog) AND
drug metabolic process (ortholog) AND
PARTICIPATES IN arachidonic acid metabolic pathway
AND linoleic acid metabolic pathway AND phase I
biotransformation pathway via cytochrome P450 AND
ASSOCIATED WITH Depressive Disorder AND
Hypertension AND Kidney Failure Chronic AND
FOUND IN intracellular membrane-bounded organelle
(ortholog) AND INTERACTS WITH 1 1-dichloroethene
AND 1 2-dichloroethene AND 17alpha-ethynylestradiol
ENCODES a protein that exhibits protein kinase activity
AND INVOLVED IN protein phosphorylation AND
INTERACTS WITH C60 fullerene AND Nnitrosodiethylamine AND ammonium chloride
INVOLVED IN maintenance of mitotic sister chromatid
cohesion (ortholog) AND post-translational protein
acetylation (ortholog) AND regulation of DNA
replication (ortholog) AND FOUND IN chromatin
(ortholog) AND chromosome centromeric region
(ortholog) AND nucleoplasm (ortholog) AND
INTERACTS WITH cefaloridine AND cisplatin AND
coumarin
ENCODES a protein that exhibits protein C-terminus
binding AND receptor binding AND FOUND IN
intracellular membrane-bounded organelle (ortholog)
AND INTERACTS WITH 2 3 7 8tetrachlorodibenzodioxine AND 2 4-dinitrotoluene AND
ammonium chloride
INTERACTS WITH 17alpha-ethynylestradiol AND
bis(2-ethylhexyl) phthalate AND bisphenol A
ENCODES a protein that exhibits immunoglobulin
receptor binding (ortholog) AND non-membrane
spanning protein tyrosine kinase activity (ortholog) AND
phosphatidylinositol binding (ortholog) AND
INVOLVED IN peptidyl-tyrosine phosphorylation
(ortholog) AND positive regulation of actin cytoskeleton
reorganization (ortholog) AND positive regulation of
microtubule polymerization (ortholog) AND
PARTICIPATES IN interleukin-4 signaling pathway
AND vascular endothelial growth factor signaling
pathway AND FOUND IN cytoplasm (ortholog) AND
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A virus
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cytoplasmic vesicle (ortholog) AND extrinsic to internal
side of plasma membrane (ortholog) AND INTERACTS
WITH C60 fullerene AND 2 3 7 8tetrachlorodibenzodioxine (ortholog) AND N-methyl-N'nitro-N-nitrosoguanidine (ortholog)
ENCODES a protein that exhibits metalloendopeptidase
inhibitor activity (ortholog) AND INVOLVED IN
binding of sperm to zona pellucida (ortholog) AND
negative regulation of endopeptidase activity (ortholog)
AND single fertilization (ortholog) AND FOUND IN
extracellular space (inferred) AND INTERACTS WITH
ammonium chloride AND cadmium dichloride AND
clofibrate
FOUND IN extracellular region (inferred) AND
INTERACTS WITH N-acetyl-L-cysteine AND Nnitrosodiethylamine AND diuron
ENCODES a protein that exhibits protein tyrosine kinase
activator activity (ortholog) AND receptor agonist
activity (ortholog) AND vascular endothelial growth
factor receptor 2 binding (ortholog) AND INVOLVED
IN apoptotic process AND negative regulation of cell
growth AND negative regulation of leukocyte
chemotaxis AND PARTICIPATES IN Bone
morphogenetic proteins signaling pathway AND
FOUND IN cell surface AND extracellular space AND
INTERACTS WITH 1 1 1-trichloro-2 2-bis(4hydroxyphenyl)ethane AND 1 2 4-trimethylbenzene
AND 2-amino-2-deoxy-D-glucopyranose
ENCODES a protein that exhibits DNA binding
(ortholog) AND sequence-specific DNA binding RNA
polymerase II transcription factor activity (ortholog)
AND INVOLVED IN central nervous system
development (ortholog) AND cochlea morphogenesis
(ortholog) AND ectoderm development (ortholog) AND
FOUND IN nucleus (ortholog) AND INTERACTS
WITH diuron AND 2 3 7 8-tetrachlorodibenzodioxine
(ortholog) AND 5-fluorouracil (ortholog)
INVOLVED IN phagocytosis engulfment AND
response to antibiotic AND response to drug AND
ASSOCIATED WITH Acute Kidney Injury AND
Cardio-Renal Syndrome AND Colitis AND FOUND IN
apical plasma membrane AND cell surface AND
cytoplasm AND INTERACTS WITH 1-naphthyl
isothiocyanate AND 11-deoxycorticosterone AND 4 4'diaminodiphenylmethane
ENCODES a protein that exhibits coreceptor activity
(ortholog) AND INVOLVED IN BMP signaling
pathway (ortholog) AND iron ion homeostasis
(ortholog) AND positive regulation of transcription from
RNA polymerase II promoter (ortholog) AND
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PARTICIPATES IN Bone morphogenetic proteins
signaling pathway AND ASSOCIATED WITH
Hemochromatosis (ortholog) AND FOUND IN
basolateral plasma membrane AND cell surface
(ortholog) AND extracellular space (ortholog) AND
INTERACTS WITH 2 3 7 8-tetrachlorodibenzodioxine
AND C60 fullerene AND cefaloridine
ENCODES a protein that exhibits 3-beta-hydroxy-delta5steroid dehydrogenase activity; steroid delta-isomerase
activity; INVOLVED IN androgen biosynthetic process;
C21-steroid hormone biosynthetic process; hippocampus
development; PARTICIPATES IN cortisol biosynthetic
pathway; estradiol biosynthetic pathway; steroid
hormone biosynthetic pathway; ASSOCIATED WITH
Hyperprolactinemia; Hypertension; FOUND IN
mitochondrial inner membrane (ortholog); mitochondrial
intermembrane space (ortholog); INTERACTS WITH ()-citrinin; 1,1,1-trichloro-2,2-bis(4hydroxyphenyl)ethane; 17beta-estradiol
ENCODES a protein that exhibits mRNA binding
(ortholog) AND FOUND IN cytoplasm (ortholog) AND
nucleus (ortholog) AND ribonucleoprotein complex
(ortholog) AND INTERACTS WITH L-methionine
(ortholog) AND bisphenol A (ortholog) AND choline
(ortholog)
ENCODES a protein that exhibits ion channel binding
AND potassium channel regulator activity AND
sequence-specific DNA binding AND INVOLVED IN
intracellular protein transport AND behavioral response
to pain (ortholog) AND negative regulation of
transcription from RNA polymerase II promoter
(ortholog) AND PARTICIPATES IN calcium/calciummediated signaling pathway AND FOUND IN axon
AND axon terminus AND dendrite AND INTERACTS
WITH ammonium chloride AND tetrachloromethane
AND 2 3 7 8-tetrachlorodibenzodioxine (ortholog)
ENCODES a protein that exhibits serine-type
endopeptidase activity (inferred) AND INVOLVED IN
positive regulation of vasoconstriction AND
INTERACTS WITH cyclosporin A AND sirolimus
AND tacrine
INVOLVED IN chromosome segregation (ortholog)
AND mitotic anaphase (ortholog) AND mitotic sister
chromatid segregation (ortholog) AND FOUND IN
kinetochore (ortholog) AND microtubule plus end
(ortholog) AND mitotic spindle (ortholog) AND
INTERACTS WITH 17alpha-ethynylestradiol AND Nnitrosodiethylamine AND cefaloridine
INVOLVED IN mitotic cell cycle checkpoint (ortholog)
AND FOUND IN kinetochore microtubule (ortholog)
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AND spindle pole (ortholog) AND INTERACTS WITH
cefaloridine AND (-)-epigallocatechin 3-gallate
(ortholog) AND 2 3 7 8-tetrachlorodibenzodioxine
(ortholog)
ENCODES a protein that exhibits structural molecule
activity (inferred) AND INVOLVED IN hair follicle
morphogenesis (ortholog) AND intermediate filament
organization (ortholog) AND FOUND IN cytoplasm
(inferred) AND intermediate filament (inferred) AND
INTERACTS WITH L-methionine (ortholog) AND
choline (ortholog) AND dimethylarsinic acid (ortholog)
ENCODES a protein that exhibits scavenger receptor
activity (inferred) AND INVOLVED IN cell adhesion
(inferred) AND FOUND IN extracellular matrix
(ortholog) AND extracellular vesicular exosome
(ortholog) AND INTERACTS WITH 17alphaethynylestradiol AND 17beta-estradiol AND 2 3 7 8tetrachlorodibenzodioxine
null

0.772193878

2.108727634

0.590089574

2.192901147

0.868616408

2.938463796

0.720173027

4.09776505

INTERACTS WITH fonofos (ortholog); parathion
(ortholog); terbufos (ortholog)

1.014978436

2.472776597

INTERACTS WITH arsenic atom (ortholog) AND
hydralazine (ortholog) AND valproic acid (ortholog)

0.658975121

2.321353547

0.822319504

2.797529061

0.867851363

2.42845486

ENCODES a protein that exhibits calcium ion binding
(inferred) AND growth factor binding (inferred) AND
heparin binding (inferred) AND ASSOCIATED WITH
Glaucoma 3 Primary Congenital D (ortholog) AND
Tooth Agenesis Selective 6 (ortholog) AND FOUND
IN extracellular matrix (ortholog) AND extracellular
space (ortholog) AND extracellular vesicular exosome
(ortholog) AND INTERACTS WITH 17alphaethynylestradiol AND N-nitrosodiethylamine AND
ammonium chloride
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ENCODES a protein that exhibits collagen binding
(ortholog) AND INVOLVED IN cartilage development
AND response to growth factor stimulus AND response
to organic cyclic compound AND ASSOCIATED WITH
Fibrosis AND Myocardial Reperfusion Injury AND
Spinal Cord Injuries AND FOUND IN proteinaceous
extracellular matrix AND extracellular matrix (ortholog)
AND extracellular space (ortholog) AND INTERACTS
WITH 17alpha-ethynylestradiol AND N-ethyl-Nnitrosourea AND ammonium chloride
INVOLVED IN extracellular fibril organization
(ortholog) AND PARTICIPATES IN Notch signaling
pathway AND FOUND IN extracellular matrix
(ortholog) AND INTERACTS WITH dexamethasone
AND diuron AND perfluorooctane-1-sulfonic acid
ENCODES a protein that exhibits calcium ion binding
AND methylated-DNA-[protein]-cysteine Smethyltransferase activity AND methyltransferase
activity (ortholog) AND INVOLVED IN DNA
dealkylation involved in DNA repair AND cellular
response to ionizing radiation AND cellular response to
organic cyclic compound AND ASSOCIATED WITH
Colonic Neoplasms AND Melanoma AND Bile Duct
Neoplasms (ortholog) AND FOUND IN nucleus AND
INTERACTS WITH ( )-pilocarpine AND 2 3 7 8tetrachlorodibenzodioxine AND 2 4-dinitrotoluene
ENCODES a protein that exhibits protein transporter
activity AND protein complex binding (ortholog) AND
INVOLVED IN caveolin-mediated endocytosis AND
cellular response to cholesterol AND protein transport
AND ASSOCIATED WITH Megalencephalic
leukoencephalopathy with subcortical cysts (ortholog)
AND FOUND IN caveola AND clathrin-coated vesicle
AND cytoplasmic vesicle AND INTERACTS WITH 2
3 7 8-tetrachlorodibenzodioxine AND 2 4-dinitrotoluene
AND C60 fullerene
ENCODES a protein that exhibits G-protein coupled
receptor activity (inferred) AND FOUND IN integral to
membrane (inferred) AND plasma membrane (inferred)
AND INTERACTS WITH 2 3 7 8tetrachlorodibenzodioxine (ortholog)
ENCODES a protein that exhibits heparin binding AND
identical protein binding AND protein kinase C binding
AND INVOLVED IN induction of apoptosis AND
positive regulation of ossification AND protein
homotrimerization AND ASSOCIATED WITH
abnormal craniofacial bone morphology AND
ASSOCIATED WITH Craniosynostoses AND FOUND
IN cytoplasm AND extracellular space AND nuclear
envelope (ortholog) AND INTERACTS WITH 17alpha-
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ethynylestradiol AND ammonium chloride AND
dichlorine
FOUND IN mitochondrion (ortholog) AND
INTERACTS WITH 17alpha-ethynylestradiol AND 2methoxyethanol AND N-nitrosodiethylamine

0.691604782

2.930527011

0.640118534

2.134991422

0.816829673

2.843496686

ENCODES a protein that exhibits leucine zipper domain
binding (ortholog) AND transcription coactivator
activity (ortholog) AND INVOLVED IN chromosome
segregation (ortholog) AND FOUND IN MIS12/MIND
type complex (ortholog) AND INTERACTS WITH
cisplatin AND 2-methylcholine (ortholog) AND 4 4'diaminodiphenylmethane (ortholog)
INTERACTS WITH N-nitrosodiethylamine AND alltrans-retinoic acid AND diuron

0.679702364

2.589740252

0.709869718

2.307354938

ENCODES a protein that exhibits identical protein
binding (ortholog) AND protein kinase binding
(ortholog) AND INVOLVED IN cytokinesis (ortholog)
AND FOUND IN cytoplasm (ortholog) AND
microtubule cytoskeleton (ortholog) AND nucleus
(ortholog) AND INTERACTS WITH 2acetamidofluorene AND 2-amino-2-deoxy-Dglucopyranose AND aldehydo-D-glucosamine
ENCODES a protein that exhibits hormone activity
(inferred) AND FOUND IN extracellular region
(inferred) AND INTERACTS WITH ammonium
chloride AND bisphenol A

0.799037232

3.684119167

1.027358136

2.033813612

ENCODES a protein that exhibits threonine-type
endopeptidase activity (inferred) AND INVOLVED IN
antigen processing and presentation (ortholog) AND
PARTICIPATES IN ubiquitin/proteasome degradation
pathway AND ASSOCIATED WITH Colorectal
Neoplasms (ortholog) AND Diabetes Mellitus Type 1
(ortholog) AND Esophageal Neoplasms (ortholog) AND
FOUND IN proteasome core complex (ortholog) AND
spermatoproteasome complex (ortholog) AND
INTERACTS WITH 1 3-dinitrobenzene AND 17alphaethynylestradiol AND 2 3 7 8-tetrachlorodibenzodioxine
ENCODES a protein that exhibits lipid binding AND
oxidoreductase activity acting on single donors with
incorporation of molecular oxygen incorporation of two

0.658897547

2.277446527

Yes

0.805086205

2.312262692

Yes

INTERACTS WITH 2 3 7 8-tetrachlorodibenzodioxine
AND N-nitrosodiethylamine AND benzo[a]pyrene
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atoms of oxygen AND enzyme binding (ortholog) AND
INVOLVED IN angiogenesis AND bone mineralization
AND cellular response to ATP AND PARTICIPATES
IN sphingosine 1-phosphate signaling pathway AND
Leishmania infection pathway AND arachidonic acid
metabolic pathway AND ASSOCIATED WITH Acute
Kidney Injury AND Acute Lung Injury AND
Adenocarcinoma AND FOUND IN caveola AND
cytoplasm AND protein complex AND INTERACTS
WITH (-)-epigallocatechin 3-gallate AND (R)-lipoic
acid AND (R)-noradrenaline
ENCODES a protein that exhibits hormone activity AND
peptide hormone receptor binding (ortholog) AND
INVOLVED IN adenylate cyclase-activating G-protein
coupled receptor signaling pathway AND endochondral
ossification (ortholog) AND endoderm development
(ortholog) AND PARTICIPATES IN Hedgehog
signaling pathway AND ASSOCIATED WITH
BRACHYDACTYLY TYPE E2 (ortholog) AND
Hypercalcemia (ortholog) AND FOUND IN Golgi
apparatus (ortholog) AND cytoplasm (ortholog) AND
intracellular (ortholog) AND INTERACTS WITH Lascorbic acid AND all-trans-retinoic acid AND
candesartan
ENCODES a protein that exhibits protein tyrosine
phosphatase activity (inferred) AND INVOLVED IN
axonogenesis (ortholog) AND ASSOCIATED WITH
Helicobacter Infections (ortholog) AND FOUND IN
perineuronal net (ortholog) AND proteinaceous
extracellular matrix (ortholog) AND INTERACTS
WITH ( )-pilocarpine AND ammonium chloride AND
cisplatin
ENCODES a protein that exhibits GTP binding (inferred)
AND INVOLVED IN protein transport (inferred) AND
small GTPase mediated signal transduction (inferred)
AND FOUND IN plasma membrane (inferred) AND
INTERACTS WITH C60 fullerene AND rosiglitazone
AND thioacetamide
ENCODES a protein that exhibits nucleic acid binding
(inferred) AND nucleotide binding (inferred)

ENCODES a protein that exhibits protein
heterodimerization activity AND retinol binding AND
retinol transporter activity AND INVOLVED IN
response to ethanol AND retinol metabolic process AND
retinol transport AND PARTICIPATES IN retinoic acid
metabolic pathway AND ASSOCIATED WITH
Diabetes Mellitus Type 2 AND Obesity AND
Avitaminosis (ortholog) AND FOUND IN extracellular
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RGD13
11558

similar to
4930506
M07Rik
protein

RGD15
62844

similar to
serine (or
cysteine)
proteinas
e
inhibitor
clade B
member 9
similar to
OEF2

RGD15
63091

RGD15
65709

similar to
ovostatin2

Rnf40

ring
finger
protein 40
E3
ubiquitin
protein
ligase

space AND protein complex AND INTERACTS WITH
17alpha-ethynylestradiol AND 2 3 7 8tetrachlorodibenzodioxine AND N-methyl-N-nitrosurea
INTERACTS WITH 2 3 7 8-tetrachlorodibenzodioxine
AND 3H-1 2-dithiole-3-thione AND benzo[a]pyrene
(ortholog)
INTERACTS WITH dibutyl phthalate AND furan AND
copper atom (ortholog)

0.663521893

1.927202011

0.611118691

2.394147272

ENCODES a protein that exhibits hydroxyisourate
hydrolase activity (inferred) AND INVOLVED IN
purine nucleobase metabolic process (inferred) AND
transport (inferred) AND PARTICIPATES IN purine
metabolic pathway AND INTERACTS WITH 2 3 7 8tetrachlorodibenzodioxine AND mercaptopurine AND
purine-6-thiol
ENCODES a protein that exhibits kinase binding
(inferred) AND INVOLVED IN axonogenesis AND
FOUND IN axon (inferred) AND cytosol (inferred)
AND INTERACTS WITH 2 3 7 8tetrachlorodibenzodioxine AND (-)-epigallocatechin 3gallate (ortholog) AND benzo[a]pyrene (ortholog)
INTERACTS WITH cisplatin

-1.240507347

-4.159261603

0.643903769

2.319702918

1.668952038

3.066907682

ASSOCIATED WITH Tumoral Calcinosis
Normophosphatemic Familial (ortholog) AND FOUND
IN cytoplasm (ortholog) AND intracellular membranebounded organelle (ortholog) AND INTERACTS WITH
chloroprene AND diethylstilbestrol AND (-)epigallocatechin 3-gallate (ortholog)
ENCODES a protein that exhibits endopeptidase
inhibitor activity (inferred) AND FOUND IN
extracellular space (inferred) AND INTERACTS WITH
indole-3-methanol AND sodium dichromate
ENCODES a protein that exhibits protein complex
binding AND syntaxin-1 binding AND ubiquitinprotein ligase activity AND INVOLVED IN ubiquitindependent protein catabolic process AND histone H2B
ubiquitination (ortholog) AND histone
monoubiquitination (ortholog) AND FOUND IN neuron
projection AND protein complex AND HULC complex
(ortholog) AND INTERACTS WITH 2 3 7 8tetrachlorodibenzodioxine AND 2 4-dinitrotoluene AND

0.740667222

2.387430322

1.0581821

2.101246609

-0.605638319

-2.577830214
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Yes

Rp1h

cylindro
matosis
(turban
tumor
syndrome
)

Rrm2

ribonucle
otide
reductase
M2

RT1Db1

RT1 class
II locus
Db1

Sass6

spindle
assembly
6
homolog

ammonium chloride
ENCODES a protein that exhibits Lys63-specific
deubiquitinase activity (ortholog); proline-rich region
binding (ortholog); protein kinase binding (ortholog);
INVOLVED IN necroptotic process (ortholog); negative
regulation of canonical Wnt signaling pathway
(ortholog); negative regulation of NF-kappaB import into
nucleus (ortholog); PARTICIPATES IN nuclear factor
kappa B signaling pathway; tumor necrosis factor
mediated signaling pathway; Retinoic acid-inducible
gene (RIG) I-like receptor signaling pathway;
ASSOCIATED WITH Familial cylindromatosis
(ortholog); Skin Neoplasms (ortholog);
Trichoepithelioma multiple familial (ortholog); FOUND
IN centrosome (ortholog); cytoplasmic microtubule
(ortholog); cytosol (ortholog); INTERACTS WITH
furan; methapyrilene; valproic acid
ENCODES a protein that exhibits ribonucleosidediphosphate reductase activity thioredoxin disulfide as
acceptor (ortholog) AND INVOLVED IN mitotic cell
cycle AND positive regulation of cell proliferation AND
pyrimidine nucleobase metabolic process AND
PARTICIPATES IN glutathione metabolic pathway
AND p53 signaling pathway AND purine metabolic
pathway AND ASSOCIATED WITH Endometrial
Neoplasms AND Urinary Bladder Neoplasms AND
Breast Neoplasms (ortholog) AND FOUND IN nuclear
envelope AND INTERACTS WITH 17alphaethynylestradiol AND N-nitrosodiethylamine AND
cefaloridine
ENCODES a protein that exhibits peptide antigen
binding (ortholog) AND INVOLVED IN T-helper 1
type immune response (ortholog) AND antigen
processing and presentation of exogenous peptide antigen
via MHC class II (ortholog) AND detection of bacterium
(ortholog) AND PARTICIPATES IN interleukin-12
signaling pathway AND Leishmania infection pathway
AND Mycobacterium tuberculosis infection pathway
AND ASSOCIATED WITH Addison Disease (ortholog)
AND Alzheimer Disease (ortholog) AND AntiGlomerular Basement Membrane Disease (ortholog)
AND FOUND IN external side of plasma membrane
(ortholog) AND late endosome membrane (ortholog)
AND lysosomal membrane (ortholog) AND
INTERACTS WITH 3H-1 2-dithiole-3-thione AND Nnitrosodiethylamine AND amitriptyline
INVOLVED IN centriole replication (ortholog) AND
centrosome duplication (ortholog) AND FOUND IN
centriole (ortholog) AND centrosome (ortholog) AND
INTERACTS WITH (-)-epigallocatechin 3-gallate
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-1.032160361

-2.06854147

Yes

0.662952702

3.042839946

Yes

0.879445692

2.467619932

Yes

0.694572707

2.243878548

Scg2

Scgb1c
1

Serpinc
1

(C.
elegans)
secretogr
anin II

secretogl
obin
family 1C
member 1
serpin
peptidase
inhibitor
clade C
(antithro
mbin)
member 1

Slc15a3

solute
carrier
family 15
member 3

Snap25

synaptoso
malassociate
d protein
25

Socs2

suppresso
r of
cytokine
signaling
2

(ortholog) AND 2 3 7 8-tetrachlorodibenzodioxine
(ortholog) AND 4-hydroxynon-2-enal (ortholog)
ENCODES a protein that exhibits chemoattractant
activity (ortholog) AND cytokine activity (ortholog)
AND INVOLVED IN MAPK cascade (ortholog) AND
angiogenesis (ortholog) AND cellular component
movement (ortholog) AND FOUND IN secretory
granule AND extracellular space (ortholog) AND
INTERACTS WITH (S)-nicotine AND 1 3dinitrobenzene AND Delta(9)-tetrahydrocannabinol
FOUND IN extracellular region (inferred) AND
INTERACTS WITH 17alpha-ethynylestradiol AND
bisphenol A AND genistein
ENCODES a protein that exhibits heparin binding AND
serine-type endopeptidase inhibitor activity AND
protease binding (ortholog) AND INVOLVED IN
negative regulation of inflammatory response AND
response to nutrient AND PARTICIPATES IN glypican
signaling pathway AND coagulation cascade pathway
AND complement system pathway AND
ASSOCIATED WITH Endotoxemia AND Inflammation
AND Jaundice AND FOUND IN extracellular space
AND INTERACTS WITH 2 4-dinitrotoluene AND 2 6dinitrotoluene AND paracetamol
ENCODES a protein that exhibits proton-dependent
oligopeptide secondary active transmembrane transporter
activity (inferred) AND symporter activity (inferred)
AND INVOLVED IN protein transport (inferred) AND
FOUND IN lysosomal membrane AND INTERACTS
WITH ammonium chloride AND cefaloridine AND
chloroprene
ENCODES a protein that exhibits SNARE binding AND
myosin binding AND protein N-terminus binding AND
INVOLVED IN axonogenesis AND calcium iondependent exocytosis of neurotransmitter AND
endosomal transport AND PARTICIPATES IN insulin
secretion pathway AND ASSOCIATED WITH Down
Syndrome (ortholog) AND FOUND IN SNARE
complex AND actin cytoskeleton AND axon AND
INTERACTS WITH C60 fullerene AND ammonium
chloride AND arsenite(3-)
ENCODES a protein that exhibits growth hormone
receptor binding (ortholog) AND insulin-like growth
factor receptor binding (ortholog) AND INVOLVED IN
aging AND response to peptide hormone stimulus AND
cellular response to hormone stimulus (ortholog) AND
PARTICIPATES IN Jak-Stat signaling pathway AND
interleukin-2 signaling pathwayinsulin signaling pathway
AND ASSOCIATED WITH Sepsis AND Spinal Cord
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1.855872057

2.096114031

-1.096292096

-3.920606626

-0.824421779

-2.318811156

0.671338592

2.790907733

-0.649618657

-2.337333133

Yes

1.2336994

2.352739818

Yes

Yes

Injuries AND Breast Neoplasms (ortholog) AND
INTERACTS WITH 1 3-dinitrobenzene AND 3H-1 2dithiole-3-thione AND ammonium chloride
Spp1
Stk32c

serine/thr
eonine
kinase
32C

Syt10

synaptota
gmin X

Tap1

transporte
r 1 ATPbinding
cassette
subfamily B
(MDR/T
AP)

Timp1

TIMP
metallope
ptidase
inhibitor
1

Tmsb1
0

thymosin
beta 10

ENCODES a protein that exhibits ATP binding (inferred)
AND protein serine/threonine kinase activity (inferred)
AND INTERACTS WITH 17beta-estradiol AND
17alpha-ethynylestradiol (ortholog) AND 2 3 7 8tetrachlorodibenzodioxine (ortholog)
ENCODES a protein that exhibits identical protein
binding (ortholog) AND protein heterodimerization
activity (ortholog) AND protein homodimerization
activity (ortholog) AND INVOLVED IN response to
stress AND FOUND IN cell junction (inferred) AND
integral to membrane (inferred) AND synaptic vesicle
membrane (inferred) AND INTERACTS WITH
ammonium chloride AND bis(2-ethylhexyl) phthalate
AND bisphenol A
ENCODES a protein that exhibits ADP binding AND
ATP binding AND ATPase activity AND INVOLVED
IN ATP catabolic process AND peptide transport AND
protection from natural killer cell mediated cytotoxicity
AND PARTICIPATES IN antigen processing and
presentation pathway AND phagocytosis pathway AND
primary immunodeficiency disease pathway AND
ASSOCIATED WITH Alveolitis Extrinsic Allergic
(ortholog) AND Arthritis Reactive (ortholog) AND
Asthma (ortholog) AND FOUND IN TAP complex
AND intracellular membrane-bounded organelle AND
integral to endoplasmic reticulum membrane (ortholog)
AND INTERACTS WITH 2 6-dinitrotoluene AND 2nitrofluorene AND 4-(N-nitrosomethylamino)-1-(3pyridyl)butan-1-one
ENCODES a protein that exhibits protease binding AND
metalloendopeptidase inhibitor activity (ortholog) AND
INVOLVED IN aging AND cartilage development AND
cell activation AND PARTICIPATES IN interleukin-6
signaling pathway AND ASSOCIATED WITH Brain
Injuries AND Cholestasis AND Diabetes Mellitus
Experimental AND FOUND IN extracellular matrix
AND basement membrane (ortholog) AND
proteinaceous extracellular matrix (ortholog) AND
INTERACTS WITH (S)-colchicine AND 1 2 4trimethylbenzene AND 1-naphthyl isothiocyanate
ENCODES a protein that exhibits actin monomer binding
(inferred) AND INVOLVED IN actin cytoskeleton
organization (inferred) AND sequestering of actin
monomers (inferred) AND spermatid development
(inferred) AND FOUND IN cytoplasm (inferred) AND
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0.703696953

2.403035612

Yes

-1.947577257

-2.964186019

0.808265442

2.623735972

0.674822925

2.019832933

Yes

0.960824309

1.967044627

Yes

1.003384925

3.127600457

Tnfrsf1
2a

Ttk

Xkr4

tumor
necrosis
factor
receptor
superfami
ly
member
12a
Ttk
protein
kinase
XK Kell
blood
group
complex
subunitrelated
family
member 4

cytoskeleton (inferred) AND INTERACTS WITH
17alpha-ethynylestradiol AND 2 3 7 8tetrachlorodibenzodioxine AND 2-nitrofluorene
INVOLVED IN cell adhesion (ortholog) AND cell death
(ortholog) AND positive regulation of axon extension
(ortholog) AND PARTICIPATES IN cytokine mediated
signaling pathway AND FOUND IN cell surface
(ortholog) AND plasma membrane (ortholog) AND
ruffle (ortholog) AND INTERACTS WITH 1 3dinitrobenzene AND 2 3 7 8-tetrachlorodibenzodioxine
AND 2 4-dinitrotoluene
ENCODES a protein that exhibits identical protein
binding (ortholog) AND PARTICIPATES IN cell cycle
pathway mitotic AND INTERACTS WITH cefaloridine
AND cisplatin AND lithium atom
FOUND IN integral to membrane (inferred) AND
INTERACTS WITH C60 fullerene AND cadmium
dichloride
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0.897563874

3.039993412

0.858999329

2.488305361

0.808544465

2.092256329

Yes

References

Alberti, G., Zimmet, P., Shaw, J. & Grundy, S. M. (2006). The IDF consensus worldwide
definition of the metabolic syndrome. Retrieved March 18, 2014, from
http://www.idf.org/webdata/docs/IDF_Meta_def_final.pdf
Animal models of disease: Metabolic, renal, and cardiovascular. (2011). Retrieved March 20,
2014, from
http://www.criver.com/files/pdfs/rms/rm_rm_d_animal_models_of_disease.aspx
Bloomgarden, Z. T. (2004). Definitions of the insulin resistance syndrome: The 1st world
congress on the insulin resistance syndrome. Diabetes Care, 27(3), 824-830.
Choi, J. K., Yu, U., Kim, S., & Yoo, O. J. (2003). Combining multiple microarray studies and
modeling interstudy variation. Bioinformatics (Oxford, England), 19 Suppl 1, i84-90.
Frayn, K. N. (2010). Metabolic regulation (3rd ed.). Oxford, United Kingdom: Wiley-Blackwell.
Gobal, F., Deshmukh, A., Shah, S., & Mehta, J. L. (2011). Triad of metabolic syndrome, chronic
kidney disease, and coronary heart disease with a focus on microalbuminuria death by
overeating. Journal of the American College of Cardiology, 57(23), 2303-2308.
doi:10.1016/j.jacc.2011.02.027; 10.1016/j.jacc.2011.02.027
Grundy, S. M. (2007). Metabolic syndrome: A multiplex cardiovascular risk factor. The Journal
of Clinical Endocrinology and Metabolism, 92(2), 399-404. doi:10.1210/jc.2006-0513
Grundy, S. M. (2012). Pre-diabetes, metabolic syndrome, and cardiovascular risk. Journal of the
American College of Cardiology, 59(7), 635-643. doi:10.1016/j.jacc.2011.08.080;
10.1016/j.jacc.2011.08.080
Grundy, S. M., Brewer, H. B.,Jr, Cleeman, J. I., Smith, S. C.,Jr, Lenfant, C., National Heart,
Lung, and Blood Institute, & American Heart Association. (2004). Definition of metabolic
syndrome: Report of the national heart, lung, and blood institute/american heart
association conference on scientific issues related to definition. Arteriosclerosis,
Thrombosis, and Vascular Biology, 24(2), e13-8.
doi:10.1161/01.ATV.0000111245.75752.C6
Harlan Laboratories. (2014). Zucker obese rats. Retrieved 4/16, 2014, from
http://www.harlan.com/products_and_services/research_models_and_services/research_m
odels/zucker_obese_rats.hl
Hong, N., Oh, J., Lee, Y. -., Youn, J. C., Park, S., Lee, S. -., . . . Kang, S. -. (2014). Comparison
of association of glomerular filtration rate with metabolic syndrome in a community-based
population using the CKD-EPI and MDRD study equations. Clinica Chimica Acta, 429,
157-162. doi:10.1016/j.cca.2013.12.008

71

Hu, P., Greenwood, C. M., & Beyene, J. (2005). Integrative analysis of multiple gene expression
profiles with quality-adjusted effect size models. BMC Bioinformatics, 6, 128.
doi:10.1186/1471-2105-6-128
Laulederkind, S. J., Hayman, G. T., Wang, S. J., Smith, J. R., Lowry, T. F., Nigam, R., . . .
Shimoyama, M. (2013). Rat genome database. Brief Bioinform, doi:10.1093/bib/bbt007
Locatelli, F., Pozzoni, P., & Del Vecchio, L. (2006). Renal manifestations in the metabolic
syndrome. Journal of the American Society of Nephrology : JASN, 17(4 Suppl 2), S81-5.
doi:10.1681/ASN.2005121332
Okada, R., Yasuda, Y., Tsushita, K., Wakai, K., Hamajima, N., & Matsuo, S. (2013). The
number of metabolic syndrome components is a good risk indicator for both early- and
late-stage kidney damage. Nutrition, Metabolism, and Cardiovascular Diseases : NMCD,
doi:10.1016/j.numecd.2013.08.004; 10.1016/j.numecd.2013.08.004
Singh, A. K., & Kari, J. A. (2013). Metabolic syndrome and chronic kidney disease. Current
Opinion in Nephrology and Hypertension, 22(2), 198-203.
doi:10.1097/MNH.0b013e32835dda78; 10.1097/MNH.0b013e32835dda78
Song, J., Liu, H., Ressom, H. W., Tiwari, S., & Ecelbarger, C. M. (2008). Chronic rosiglitazone
therapy normalizes expression of ACE1, SCD1 and other genes in the kidney of obese
zucker rats as determined by microarray analysis. Experimental and Clinical
Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [and]
German Diabetes Association, 116(6), 315-325.
Stern, M. P., Williams, K., Gonzalez-Villalpando, C., Hunt, K. J., & Haffner, S. M. (2004). Does
the metabolic syndrome improve identification of individuals at risk of type 2 diabetes
and/or cardiovascular disease? Diabetes Care, 27(11), 2676-2681.
Storey, J. D., & Tibshirani, R. (2003). Statistical significance for genomewide studies.
Proceedings of the National Academy of Sciences of the United States of America,
100(16), 9440-9445. doi:10.1073/pnas.1530509100
Tusher, V. G., Tibshirani, R., & Chu, G. (2001). Significance analysis of microarrays applied to
the ionizing radiation response. Proceedings of the National Academy of Sciences of the
United States of America, 98(9), 5116-5121. doi:10.1073/pnas.091062498
Wallis, R. H., Collins, S. C., Kaisaki, P. J., Argoud, K., Wilder, S. P., Wallace, K. J., . . .
Gauguier, D. (2008). Pathophysiological, genetic and gene expression features of a novel
rodent model of the cardio-metabolic syndrome. PloS One, 3(8), e2962.
doi:10.1371/journal.pone.0002962; 10.1371/journal.pone.0002962
Yamamuro, T., Hori, M., Nakagawa, Y., Hayashi, T., Sakamoto, S., Ohnishi, J., . . . Urayama, O.
(2013). Tickling stimulation causes the up-regulation of the kallikrein family in the

72

submandibular gland of the rat. Behavioural Brain Research, 236(1), 236-243.
doi:10.1016/j.bbr.2012.09.001; 10.1016/j.bbr.2012.09.001
Yasui, N., Kajimoto, K., Sumiya, T., Okuda, T., & Iwai, N. (2007). The monocyte chemotactic
protein-1 gene may contribute to hypertension in dahl salt-sensitive rats. Hypertension
Research : Official Journal of the Japanese Society of Hypertension, 30(2), 185-193.
doi:10.1291/hypres.30.185

73

